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ABSTRACT
Genomic DNA is constantly damaged by both internal and external genotoxins
and cellular processes. A consequence of unrepaired or misrepaired DNA damage is
genome instability, a hallmark of cancer and numerous other diseases. Eukaryotic cells
have developed complex mechanisms to repair DNA damage, which is collectively
referred to as a DNA damage response (DDR). CST (CTC1-STN1-TEN1) is a
heterotrimeric, RPA-like protein complex that binds to single stranded (ss)DNA. In
humans, CST functions in the replication and maintenance of telomeres, structures found
at the ends of linear chromosomes, as well as non-telomeric DNA. Previous studies
showed that deletion of the largest CST subunit, CTC1, results in decreased cell
proliferation and telomeric DNA damage signaling. However, the consequences of
conditional CTC1 or STN1 knockout (KO) at the cellular level have not been fully
elucidated. Consistent with previous findings, we demonstrate that CTC1 or STN1 KO
results in decreased cell proliferation, G2 arrest and RPA-bound telomeric ssDNA, which
should trigger a DDR through the ATR-CHK1 pathway. However, despite the increased
levels of telomeric RPA-ssDNA, global ATR-dependent CHK1 and p53 phosphorylation
was not detected in CTC1 and STN1 KO cells. Interestingly, we show that RPA-ssDNA
still activates ATR, leading to the phosphorylation of RPA and autophosphorylation of
ATR, and that G2 arrest is dependent on exhaustion of the telomere protection factor,
POT1 in CTC1 KO cells. These results suggest that ATR is localized and active at RPAbound telomeres but is unable to elicit a global checkpoint response through CHK1
vii

Furthermore, CTC1 or STN1 KO inhibited CHK1 phosphorylation following replication
stress due to decreased levels of the ATR activator TopBP1. Finally, we investigated
whether the phenotypes caused by CTC1 deletion can potentially be rescued by various
CTC1 mutant constructs. Preliminary studies find that TopBP1 levels can be restored
with different mutant versions of CTC1, providing clues to how different CST domains
may regulate the DDR. Overall, our results identify CST as a novel regulator of the ATRCHK1 pathway.
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CHAPTER 1
INTRODUCTION
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1.1 DNA DAMAGE, AND THE ATR-MEDIATED DNA DAMAGE RESPONSE
DNA damage can arise from both endogenous and exogenous factors, such as
replication stress, ionizing radiation and oxidation. To prevent genome instability and
disease, cells have evolved elaborate signaling pathways to sense the damage, arrest the
cell cycle and repair the DNA. This process, known as the DNA damage response
(DDR), is primarily mediated by three members of the PIKK family, namely ATM, ATR
and DNA-PK [1]. Activation of these kinases in response to DNA damage leads to the
phosphorylation of downstream effectors and stabilization of the tumor suppressor, p53.
p53 in turn induces transcription of downstream targets, such as p21, that facilitate cell
cycle arrest and eventual apoptosis or senescence, if the damage is not resolved.
ATM and DNA-PK are primarily activated in response to double-strand breaks
(DSBs), whereas ATR coordinates the repair of DNA damage arising from single
stranded (ss)DNA gaps or breaks. ATR plays a primary role in managing replication
stress during S-phase and is essential for the survival of dividing cells [2-4]. During Sphase, ssDNA can arise from uncoupling of the helicase from the replisome and
nucleolytic processing of various replication and repair intermediates [5, 6]. Once
exposed, large regions of ssDNA are quickly bound by the ssDNA binding protein, RPA
(Figure 1.1) [7]. ATRIP then associates with the RPA-bound ssDNA (RPA-ssDNA),
which localizes ATR [8]. Localization of ATR, however, is insufficient to fully activate
ATR kinase activity.
In vertebrates, two major ATR activating proteins have been identified, TopBP1
and ETAA1 [9-12]. Both proteins contain ATR activating domains (AAD) that modulate
ATR kinase activity [13]. ETAA1 was only recently discovered and less is known about
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the mechanism by which it activates ATR. However, recent work suggests that ETAA1
plays only a minor role in ATR activation during the DDR [14, 15]. Instead, ETAA1
plays a primary function in proper chromosome alignment and checkpoint activation in
metaphase as well as preventing untimely entry into G2. On the other hand, TopBP1 is
essential for ATR activation in response to ssDNA damage [12]. Localization of TopBP1
involves interaction with RPA-ssDNA and the RAD9-RAD1-HUS1 (9-1-1) complex,
which is loaded at 5’ ssDNA-dsDNA junctions [16-18]. Once activated, ATR
phosphorylates numerous downstream targets, including CHK1 and p53 [19-21]. CHK1
then promotes the degradation of CDC25A, leading to inactivation of cyclin-dependent
kinases and inhibition of replication origin firing [22]. Failure to activate the ATR-CHK1
pathway, particularly following treatment with replication inhibitors or in cancer cells
with high levels of genome instability, leads to impaired growth and cell death. Several
ATR/CHK1 inhibitors are currently in clinical trials or in development as cancer
therapeutics [23].
1.2 CST STRUCTURE AND DNA BINDING PROPERTIES
Human CST (CTC1-STN1-TEN1) is a conserved, ssDNA binding protein that
shares homology with RPA (RPA1-RPA2- RPA3) [7]. Both RPA and CST are
heterotrimeric and contain a number of oligonucleotide-oligosaccharide binding folds
(OB-folds), which are used for DNA binding and protein-protein interactions. Until
recently, the structures of human CST were limited to STN1 and TEN1 [24]. In a
groundbreaking 2020 study, Lim, et al. reported the 3.0-angstrom cryo-electron
microscopy structure of CST. CTC1 is characterized by 7 OB-folds which are responsible
for ssDNA binding and protein interactions while STN1 and TEN1 each contain a
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singular OB-Fold [25]. STN1 also contains two C-terminal winged helix-turn-helix
domains, one of which interacts with CTC1 OB-fold E [25] (Figure 1.2). Structural
studies demonstrate a high degree of structural homology between the OB-folds in CST
and RPA [24, 25]. Like RPA, human CST binds to ssDNA in the low to sub-nanomolar
range and requires multiple OB-fold for DNA binding. CST dynamically binds to ssDNA
with a minimal binding site of 16-18 nucleotides and maximal binding around 48
nucleotides [26-28]. Despite their similarities RPA and CST appear to have distinct
modes of binding and cellular function. [27-29]. For example, CST can stably bind an 18
nucleotide G-strand telomere sequence whereas binding is not observed on random or
non-telomeric sequences until they are 32-36 nucleotides in length [28]. The preference
for short G-rich sequences is facilitated in part by STN1, as mutation of key residues in
the STN1 OB-fold leads to decreased binding on short G-strand sequences [26].
Interestingly, this sequence specific binding mode is related to the G-rich nature of the
DNA sequence and not the telomere sequence per se [28].
Additional binding properties such as its preferential binding to ss-dsDNA
junctions or its ability to bind and melt certain secondary structures (such as G4s)
indicate that CST possesses a variety of DNA binding activities that allows it to function
in multiple DNA replication/repair processes which will be discussed in further detail
below [27].
1.3 ROLES OF CST IN TELOMERE REPLICATION
CST plays a critical role in telomere replication and less characterized functions
in genome-wide replication and DSB repair [26, 27, 30-35]. The natural chromosome
ends, known as telomeres, must be protected from the DDR to prevent genome instability
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in the form of chromosome fusions and degradation. Telomeric DNA ranges in length
from a few hundred base pairs in yeast to tens of kilobases in mammals [36, 37]. In
humans, telomeres consist of short tandem 5'-TTAGGG-3' repeats on the G-rich strand
and complimentary 5'-CCCTAA-3' repeats on the C-rich strand (Figure 2A). The G-rich
strand also contains a 3' ssDNA region referred to as the G-overhang [38, 39]. In
mammals, telomeres are protected by the shelterin complex (TRF1-TRF2-RAP1-TIN2TPP1-POT1) [40]. Shelterin plays a critical role in telomere end protection and
preventing the recognition of telomeres as DNA damage. The duplex DNA is bound by
TRF1 and TRF2/RAP1 whereas the G-overhang region is protected by POT1, which
complexes with TPP1 (Figure 1.3A).
During S-phase, telomeres are replicated in three distinct steps (Figure 2C) [34].
First, the duplex DNA is replicated by the conventional replication machinery. While
replication on the leading strand is presumed to reach the chromosome terminus, the
lagging strand machinery is unable to fully replicate the ends, a phenomenon known as
the end-replication problem [41, 42]. To overcome this, telomeres are extended by
telomerase, which is recruited and stimulated by TPP1/POT1 (Figure 1.3B) [43, 44].
After extension, telomerase is then dissociated from the telomere to prevent extensive Goverhang elongation and subsequent targeting by ATR for DNA repair [25, 45]. Next,
DNA polymerase α-primase (pol α) converts most of the G-overhang to duplex DNA
[46]. The remaining short G-overhang can then form a lariat structure called a telomere
loop (t-loop) to protect the DNA terminus from being recognized as DNA damage [47].
CST promotes successful replication of the telomeric duplex region. As
mentioned above, telomeres are composed of highly repetitive sequences and can form
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DNA secondary structures (G4s and t-loops), which can stall replication [48, 49]. Such
stalling can lead to unreplicated DNA or DNA breaks which are then targeted by the
DDR for repair. Previous studies showed that disruption of CST subunits leads to a delay
in telomere duplex replication and the formation of multiple telomeric signals (MTS), or
fragile telomeres [34, 35, 50-53]. MTS manifest as gaps or breaks in telomere FISH
signals on metaphase chromosomes and are similar to common fragile sites. MTS are
proposed to arise from replication stalling and consistent with this idea, CST has been
found to prevent replication failure by preventing G-4 accumulation [54] (Figure 1.4).
Together, these data suggests that CST binding to the telomere DNA is required for
telomere duplex replication [26].
CST also plays dual roles in telomere end processing, first, by inhibiting
telomerase following telomere extension and second, by facilitating C-strand fill-in
(Figure 1.3) [45]. Telomerase is suggested to elongate the telomeres through single
rounds of processive elongations which is partly mediated by POT1-TPP1 [55, 56]. After
telomerase extension of the telomere, CST binds to the G-overhang which prevents
telomerase association [29]. Additionally, CST interferes with POT1-TPP1 dependent
telomerase activity in a mechanism likely dependent on the physical interaction of CST
and POT1-TPP1 [29]. CST is essential in regulating G-overhang length, and conditional
CTC1 deletion results in extensive elongation of the G-overhang [57]. Next, telomere
processing switches from overhang elongation to C-strand fill in by pol α. CST is
proposed to facilitate this switch by stimulating DNA pol α to convert most of the Goverhang to duplex DNA, however, CST regulated fill-in does not appear to be as critical
as its ability to modulate telomerase inhibition for end protection [46, 53, 58].

6

1.4 GENOME-WIDE ROLES OF CST
Although the role of CST at the telomeres has been more broadly studied,
mounting evidence indicates that CST is a specialized genome-wide replication factor.
Three key pieces of evidence supported this initial idea. First, CTC1 and STN1 were
originally discovered as pol α accessory factors [59-61]. Second, only a fraction of STN1
foci (~20%) co-localize with telomeres [62]. Third, depletion of CST subunits leads to
signs of general genome instability, such as non-telomeric γH2AX foci, anaphase
bridges, and micronuclei [63]. In recent years, several studies have analyzed the various
roles of CST in DNA helping to facilitate replication rescue, preventing genome
instability, and promoting DNA damage repair.
During unperturbed DNA replication, multiple studies indicate a role for CST as a
multifaceted player in genome-wide replication. Previous work indicated that CST
promotes origin firing in response to genome-wide replication stress [34]. Additionally,
CST has been shown to recruit RAD51 to stalled replication forks to rescue replication at
GC-rich DNA [33]. Recently, we discovered that STN1 directly interacts with two
subunits of the replicative helicase, MCM4 and MCM7, and is involved in proper origin
licensing. By interacting with the MCM complex, CST disrupts MCM and CDT1
interaction which limits over licensing of DNA replication origins [30]. Additionally,
CST interacts with AND-1, which couples pol α to the replisome [30, 64]. Together,
these studies suggest that CST helps to regulate DNA replication origin licensing and
replisome assembly, and thereby contributes to overall genome stability.
In addition to its roles in unperturbed DNA replication, CST prevents genome
instability in response to replicative stress. Cells with depleted levels of CST show
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reduced cell viability after diverse forms of DNA damage such as HU, aphidicolin, or
methanseulphonate treatment [65]. CST also promotes dormant origin firing to rescue
stalled replication forks (Figure 1.5A) [30]. On the other hand, CST overexpression
increases cell fitness after these different damages, suggesting that CST levels are
limiting and overexpression can facilitate recovery from many types of DNA damage
[65].
In recent groundbreaking studies, CST was found to also function in DSB repair
[31, 66]. DSBs are considered to be the most deleterious types of DNA damage and are
repaired mainly through two pathways, non-homologous end joining (NHEJ) and
homologous recombination (HR) [67, 68]. HR is considered to be the more accurate
method by which DSBs are repaired, however, it is limited to S and G2 phases of the cell
cycle where a sister chromatid is present for homology directed repair [69, 70]. NHEJ, on
the other hand, is fast, highly mutagenic, and selective for two-ended DSBs [71].
Therefore, many studies have targeted HR as a way to combat cancer and the accurate
repair of DSBs in these cells. There are multiple decision points during DSB repair that
can help determine whether a DSB is repaired by NHEJ versus HR. For HR, the DSB are
resected to facilitate homology search and DNA synthesis to repair the break. On the
other hand, resection must be inhibited for NHEJ so that blunt ends of the DSB can be
ligated together. CST was found to play a role in promoting NHEJ by preventing DNA
end resection in combination with Shieldin and pol α [31, 32]. 53BP1 can help recruit
Shieldin through RIF1 which localizes CST/pol α to the resected DNA. CST/pol α then
convert the ssDNA back to duplex DNA, shifting repair towards NHEJ (Figure 1.5B) [31,
66]. The highly mutagenic nature of NHEJ versus HR provides possible targets for cancer
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therapies whereby promoting DSBs can provide synthetic lethality when HR is blocked.
PARP inhibitors (PARPi) are able to induce such lethality in HR-deficient cells, such as
those lacking BRCA1. In conjunction with this, 53BP1 was found to promote PARPi
sensitivity with the help of Shieldin/CST/pol α. In BRCA1 deficient cells, CST helps to
inhibit DSB end resection to promote NHEJ and increased cell death. However, in
BRCA1 and CST deficient cells, DSBs can be repaired through accurate HR [32].
Together, these studies indicate an essential role for CST in protecting DSBs from end
resection to promote NHEJ, and thus, creating a pathway for the synthetic lethal effects
of PARPi.
1.5 CST AND TELOMEROPATHIES
Coats plus (CP), also known as CRMCC, is a pleiotropic, autosomal recessive
disorder that is typically diagnosed in infancy or early childhood and carries high
mortality and morbidity rates [72, 73]. Loss of stem cell compartments appears to
underlie the disease. CP has common features including intrauterine growth retardation,
intracranial calcifications, retinopathy, neurological defects and gastrointestinal bleeding.
Penetrance and expression of symptoms is wide-ranging and the cause of death varies
greatly between patients, underscoring the complexity of CP. In 2012, CTC1 mutations
were identified in a number of CP patients with additional cases later reported [74-81].
Biallelic mutations in either STN1 or the shelterin component POT1 have also been
shown to cause CP [82-85]. Interestingly, characterization of cells from the CP patient
harboring POT1 mutations were shown to affect CST recruitment and positioning at the
telomere, suggesting that CST misregulation also underlies CP in this patient [84]. CTC1
mutations were also found in patients with dyskeratosis congentia (DKC) [86, 87]. DKC
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is in a class of short telomere spectrum disorders, often referred to as telomeropathies.
These disorders encompass a variety of diseases ranging from childhood bone marrow
failure disorders to adult-onset pulmonary fibrosis and liver disease [88-91]. Like CP, the
loss of stem cell compartments is thought to cause telomeropathies. CP shares common
features with DKC and other childhood telomeropathies, including bone marrow failure,
sparse and graying hair, nail dystrophy and osteopenia. Furthermore, in a case report by
Keller et al. a patient diagnosed with DKC showed intracranial calcifications and early
signs of retinopathy, indicating overlap with CP [86]. The fact that mutations in CST
subunits cause both DKC and CP suggest a common molecular etiology. Several groups
have proposed telomere shortening as the common denominator [74, 92, 93]. However,
there have been conflicting reports on whether all CP and DKC patients with mutations in
CTC1 or STN1 have shortened telomeres. At present, it is unclear whether these
differences arise from the methods used to measure telomere length and/or variations in
disease pathology from specific mutations.
Several studies have sought to determine the molecular consequences of CP
mutations. CTC1 mutations occur as compound heterozygotes with one allele typically
harboring a frameshift or nonsense mutation and the other allele a missense mutation.
Expression of the equivalent nonsense and frameshift mutants in mice produced truncated
proteins that either express poorly or not at all, suggesting that these alleles are nonfunctional [92]. Indeed, these mutants are unable to bind telomeric DNA, localize to
telomeres or interact with STN1. Analysis of CTC1 missense mutants showed
hypomorphic phenotypes in CST, with some affecting DNA binding activity and
telomeric association, while others led to changes in nuclear localization or decreased
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interaction with pol alpha [93]. Yet, no common telomeric phenotype was observed
across the mutants, opening the possibility that these mutations also affect the nontelomeric roles of CST. In agreement with this idea, cells from CP patients, with STN1
mutation, had telomere dysfunction as well as signs of general genomic instability and
DNA replication defects [85]. Together, these results argue that defects in both telomeric
and non-telomeric functions of CST contribute to CP, which may help explain the
diversity of symptoms and their expression. To date no molecular studies of DKC
patient-derived cells harboring CTC1 mutations have been performed. However, stromal
cells collected from one patient showed severe premature senescence [86], which was
also observed in CP patient cells with STN1 and POT1 mutations. The authors of this
study suggest that expression of both DKC and CP features may relate to environmental
or genetic modifiers. Thus, further characterization of CP and DKC patient-derived cells
will be critical to understand CST and help in the treatment and management of these
diseases.
1.6 CST AND CANCER
Alteration in the expression of CST subunits has been linked to increased cancer
risk and poor prognosis of survival [94-97]. For example, decreased CTC1 or STN1 (also
known as OBFC1) gene expression leads to decreased survival in breast, lung and gastric
cancer patients [98]. SNPs in CTC1 and STN1 have also been associated with an
increased risk of cancer development. These findings are consistent with the fact that
depletion of CST subunits leads to hallmarks of cancer, including telomere dysfunction
and increased genome instability (anaphase bridges, micronuclei, DNA damage) [29, 33,
34, 51, 52, 63]. Furthermore, increased CTC1 expression leads to radioresistance in
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melanoma cancer cell lines by preventing telomere shortening and apoptosis [96]. While
further analysis is required, these results indicate that CST levels are tightly regulated to
preserve genome stability and suggest that CST may be a promising target for cancer
therapy.
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Figure 1.1 Model of ATR activation in response to ssDNA. In the
event of ssDNA damage, the DNA is quickly bound by RPA. ATRIP then
associates with RPA-ssDNA which localizes ATR to the damage site.
Independently, the 9-1-1 complex binds at the ds-ssDNA junction and
localizes TopBP1 to the damage site. TopBP1 interacts and activates ATR
which will then phosphorylate CHK1 and other downstream targets.
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Figure 1.2 Schematic representation of domain structures of the CST
complex. CST is a ssDNA binding protein characterized by multiple OB-folds.
CTC1 is 1217 amino acids (aa) long and contains 7 OB-folds. OB-E and OB-F
contain the ssDNA binding domains. CTC1 interacts with the 368aa protein,
STN1, through binding of OB-E of CTC1 to the single STN1 OB-fold and OBG of CTC1 to the first wHTH domain of STN1. STN1 acts as the bridge
between CTC1 and TEN1 (123aa) by interacting with the single OB-fold of
TEN1.
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Figure 1.3 Overview of the roles of CST at telomeres. (A) Telomeres are bound
by the shelterin complex (TRF1-TRF2-RAP1-TIN2-TPP1-POT1) and the 1236
CST complex (CTC1-STN1-TEN1), which aid in telomere maintenance. (B) After
telomere duplex replication the leading strand is processed to produce a Goverhang. Telomerase then extends the G-overhangs. To prevent G-overhang
hyperextension, CST is localized to telomeres by TPP1 and inhibits telomerase
activity. Additionally, CST promotes C-strand fill-in by stimulating pol α. After
telomere processing, the shelterin complex rebinds.
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Figure 1.4 Model of G-quadruplex (G4) melting and fork restart
during telomere duplex replication. The G4 secondary structure
can form in G-rich sequences of DNA such as the telomeres. In the
absence of CST, replication is stalled. CST resolves or prevents G4
formation to promote replication restart.
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Figure 1.5 Roles of CST in genome wide replication and the DNA damage
response. (A) In the event of replication stalling, CST promotes the firing of
dormant or unfired origins which rescue the stalled replication fork and
promotes DNA replication. (B) In response to DSBs, 53BP1 is localized through
its interaction with γH2AX. 53BP1 then interacts with RIF1, which localizes the
Shieldin complex. Shieldin inhibits long-range resection by preventing access to
the resected DNA and reverses resection through its interaction with CST-pol α,
which can mediate fill-in of the resected DNA. This promotes repair of the
break by NHEJ. (P: phosphorylation; Ub: ubiquitination).
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CHAPTER 2
CST IS A REGULATOR OF CELL CYCLE PROGRESSION BY PROMOTING
TELOMERE PROTECTION
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2.1: INTRODUCTION
Previous work demonstrated that conditional deletion of human CTC1 leads to
growth inhibition and unregulated lengthening of the G-overhang by telomerase as well
as shortening of telomeres from the inability to perform C-strand fill-in [57]. Since
telomeres resemble DNA breaks, they must be protected from recognition by the DDR.
Telomere G-overhangs are typically protected by POT1, a member of the shelterin
complex. However, these extended G-overhangs in CTC1 deleted cells exhaust the
cellular pools of POT1, leading to telomeric RPA-ssDNA and telomeric γH2AX, a
marker of DNA damage. While this accumulation of RPA-ssDNA is predicted to elicit
activation of the ATR-CHK1 pathway, this was not directly tested in previous studies
[57, 99].
To more precisely examine the effects of conditional CTC1 KO, we performed
time course analysis of the cell cycle in HCT116 conditional CTC1 KO (CTC1-/-). The
HCT116 CTC1-/- cell line was previously generated by the addition of loxP sites
surrounding exon 5 of both endogenous CTC1 alleles (CTC1F/F) [57]. Cells were then
stably selected for expression of a Cre recombinase linked to the estrogen receptor (CreER). Addition of TAM results in localization of Cre-ER to the nucleus and removal of
exon 5 by Cre-induced recombination. Gene disruption was confirmed by Western blot
and PCR analysis following the addition of TAM, as previously described (Figure 2.1)
[57]. To control for possible off-target effects, a stable cell line was developed,
expressing Flag-CTC1 in the CTC1F/F line (CTC1F/F+Flag-CTC1) [57]. Following the
addition of TAM (CTC1-/-+Flag-CTC1), the endogenous CTC1 is disrupted, while the
exogenous Flag-CTC1 expression remains unchanged (Figure 2.1).
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2.2: RESULTS
2.2A: CTC1 DELETION INDUCES G2 ARREST AND APOPTOSIS BUT DOES
NOT ALTER S-PHASE PROGRESSION
Previous studies found that CTC1 deletion led to decreased proliferation and an
accumulation of G2/M arrested cells [35, 57]. In agreement with these studies, we
observed decreased cell proliferation (Figure 2.2A) and the accumulation of G2/M cells
starting around six days after conditional CTC1 deletion, which became more severe 1012 days after TAM addition (Figure 2.2B-C).
In addition to its role in telomere replication, CST aids in several aspects of
genome-wide replication, including replication of G-rich DNA, dormant origin activation
following replication stress and origin licensing [30, 34, 54, 100]. Since past studies
focused on telomere and not genome-wide replication, we tested whether CTC1 deletion
affected global replication rates. To test this, we examined the levels of DNA synthesis in
CTC1-/- cells by flow cytometry and DNA combing. Flow cytometry revealed a
significant decrease in the number of S-phase cells following CTC1 deletion (Figure
2.2B). However, the cells within S-phase retained similar levels of DNA synthesis (i.e.
EdU intensity per cell) compared to controls (Figure 2.2C). Additionally, the number of
S-phase EdU negative cells was not substantial increased (Figure 2.2B), suggesting that
global replication is not inhibited in the CTC1-/- cells under normal conditions. To
confirm this result, we performed DNA fiber analysis on day 11 after TAM addition
(Figure 2.3A-C). Again, we failed to detect any significant changes in DNA synthesis or
replication events following CTC1 deletion. These findings indicate that S-phase
progression and global DNA synthesis are not significantly altered following CTC1
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removal, which is in line with the idea that CST acts as a specialized, not general,
replication factor to promote replication at G-rich DNA or dormant origin activation
following replication stress [34, 100].
Since CTC1 deletion induces the accumulation of G2/M phase cells, we sought to
distinguish between G2 versus M-phase. Accordingly, IF was performed to assess the
number of phosphorylated Histone H3 S10 positive cells, as a readout of the mitotic
index [101]. The percentage of mitotic cells was not increased in the CTC1-/- cells
compared to controls, indicating that CTC1 deletion causes an accumulation of G2 rather
than M-phase cells (Figure 2.4). In addition, we observed an increase in the sub-G1
population (Figure 2.2C), which could arise from increased apoptosis. Indeed, we found
that CTC1 deletion led to increased apoptosis, as measured by increased caspase 3/7
activity (Figure 2.4B). Conditional CTC1 deletion also leads to increased senescence in
human and mouse cells, suggesting that both apoptosis and senescence contribute to
overall growth inhibition in CTC1-/- cells [35, 52, 57].
2.2B: CTC1 KO DOES NOT INDUCE GLOBAL ATR-CHK1 SIGNALING
Since CTC1 deletion leads to an increased number of G2 arrested cells, we next
wanted to determine the cause of this arrest. Previous work determined that loss of CTC1
increases G-overhang length, leading to RPA binding and presumably activation of the
DDR through ATR-CHK1 [57]. Nevertheless, whether the ATR-CHK1 pathway is
activated following CTC1 deletion was not directly tested. Following the accumulation of
RPA-ssDNA, ATR should be recruited leading to the phosphorylation of several
downstream ATR targets, including H2AX, CHK1 and p53. As a readout of ATR
activation, we measured the phosphorylation of CHK1 (pCHK1) S317 and S345, and p53
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S15 (p-p53 S15) in whole cell lysates collected at days 8, 11 and 13 after TAM addition
(Figure 2.5A-B). Additionally, global γH2AX levels were measured by IF (Figure 2.5C).
However, CTC1 KO did not result in detectable pCHK1 S317/S345 or p-p53 S15,
suggesting that the ATR-CHK1 pathway is not globally activated in CTC1-/- cells under
these conditions. Total γH2AX levels were also not increased, implying that cells do not
contain high levels of DNA damage signaling. Interestingly, while p53 S15
phosphorylation was not observed, total p53 levels were increased in the CTC1-/- cells,
suggesting activation of a DDR (Figure 2.5A). In agreement with p53 activation, p21
levels also increased starting at eight days after TAM addition (Figure 2.6A), which
corresponds to the partial G2 arrest and growth inhibition in the CTC1-/- cells (Figure
2.2). Finally, CTC1-/- cells were treated with siRNA to p53 to determine whether the G2
arrest was p53-dependent (Figure 2.6B). However, p53 knockdown did not suppress the
accumulation of G2 cells following CTC1 deletion, suggesting that p53-independent
mechanisms also promote G2 arrest following CTC1 deletion (Figure 2.6C)
2.2C ATR IS ACTIVATED AND PHOSPHORYLATES TELOMERE-BOUND
RPA IN CTC1-/- CELLS
As mentioned previously, CTC1 KO leads to telomeric RPA and γH2AX staining
on metaphase chromosomes [57]. Under normal conditions, excess RPA-ssDNA should
lead to ATR activation and CHK1 phosphorylation. Since pCHK1 was not detected
following CTC1 deletion, we determined whether ATR was active and localized to RPAbound telomeres. First, we confirmed that RPA-ssDNA was present at telomeres
following CTC1 deletion by IF-FISH to measure chromatin-bound RPA at telomeres. In
agreement with previous findings, RPA foci were increased in interphase CTC1-/- cells
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and these foci were almost exclusively at telomeres (~80%) (Figure 2.7) [57].
Interestingly, increased RPA foci typically corresponded to enlarged nuclei in CTC1-/cells (Figure 2.8A). The increased levels of chromatin-bound RPA in the CTC1-/- cells
was also confirmed by flow cytometry of pre-extracted cells (Figure 2.8B).
Recruitment of ATRIP-ATR to RPA-ssDNA typically leads to ATR-dependent
phosphorylation of RPA32 S33 (pRPA) [102]. Since pCHK1 was not detected in cell
extracts but RPA was increased at telomeres, pRPA was measured as a readout of ATR
activation (Figure 2.9). Similar to total chromatin-bound RPA, we observed a significant
increase in pRPA. This suggested that, although pCHK1 is not present in CTC1-/- cells,
ATR is active and present at telomeres. To confirm this, CTC1-/- and control cells were
treated with ATRi for 24 hours and pRPA and RPA determine (Figure 2.7B and 2.9B).
Treatment with ATRi suppressed the pRPA foci in CTC1-/- cells. However, total RPA
foci remained unchanged, indicating that the phosphorylation of RPA in the CTC1-/- cells
is ATR-dependent. A previous study also found telomeric γH2AX in CTC1-/- cells on
metaphase spreads [57]. In agreement with this study, we found that RPA-foci colocalized with γH2AX in interphase CTC1-/- cells (Figure 2.10A-B). Nevertheless, these
foci were difficult to distinguish from background γH2AX foci in the control cells
without RPA staining, which likely precluded their detection in the global γH2AX
analysis in Figure 2.5C. To more directly test ATR activation, Western blot analysis was
performed to measure the levels of autophosphorylated ATR at T1989 (pATR). In
contrast to pCHK1, pATR was significantly increased in CTC1-/- cells (Figure 2.10C).
Additionally, there was an overall increase in total ATR levels, which suggest that CTC1
deletion may alter ATR gene expression. Together, these results indicate that ATR
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localizes to telomeric RPA-ssDNA and is activated in CTC1-/- cells. However, ATR
activation is insufficient to induce detectable levels of pCHK1 S317/S345 or p-p53 S15
in the absence of CTC1 (Figure 2.5A-B).
2.2D: ATR BUT NOT ATM OR CHK1 PROMOTES G2 ARREST IN CTC1
DELETED CELLS
To assess whether ATR activation contributes to the accumulation of G2 arrested
cells following CTC1 KO, we performed flow cytometry on cells treated with the ATR
inhibitor (ATRi) VE-821 for 24 h or siRNA to ATR (Figures 2.11 and 2.12 and Tables
2.1-2). ATR inhibition or knockdown prevented the accumulation of G2/M cells
following CTC1 deletion. ATR inhibition also resulted in increased apoptosis in CTC1-/cells, as measured by caspase 3/7 activity (Figure 2.4B). As a control, cells were also
treated with siRNA to ATM or CHK1 to confirm that the increased number of G2 cells
were ATR-dependent (Figures 2.13 and 2.14 and Tables 2.3-2.4). Unlike knockdown of
ATR, depletion of ATM was unable to suppress the increase in G2 arrested cells
following CTC1 deletion. Depletion of CHK1 was also unable to suppress the increase in
G2 cells. However, these results are somewhat complicated by the fact that CHK1
knockdown leads to an overall increase in G1 and decrease in G2/M phase cells across all
cell lines (Figure 2.14C and Table 2.4). Despite alterations in the cell cycle, comparison
of the fold increase in G2/M cells between CTC1-/- and control cells was similar
following treatment with siNT (CTC1-/-/CTC1F/F/:1.39, CTC1-/-/CTC1-/-+FlagCTC1:1.29) and siCHK1 (CTC1-/-/CTC1F/F:1.30, CTC1-/-/CTC1-/-+Flag-CTC1:1.26) (see
Tables 2.1-4). Still, our results do not exclude the possibility that CHK1 may be partially
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responsible for the G2 arrest. Together, these results indicate that the accumulation of G2
arrested cells following CTC1 KO is ATR-dependent.
2.2E STN1 DELETION INDUCES G2 ARREST AND ATR SIGNALING AT
TELOMERES
Next, we evaluated the effect of conditional STN1 KO using an inducible Cas9
(iCas9) system in HeLa cells. This allowed us to confirm whether the phenotypes
observed with CTC1 deletion are due to CST function as a whole rather than specific to
CTC1 alone or HCT116 cells. To date, no human STN1 KO line has been reported,
therefore we developed a conditional STN1 KO cell line in HeLa cells. To create this cell
line, HeLa cells with Cas9 under an inducible doxycycline (Doxy) promoter were
obtained from Dr. Iain Cheeseman [103, 104]. sgRNA to STN1 were transfected into
HeLa iCas9 cells, clones were isolated, and STN1 gene disruption was measured by
Western blot (Figure 2.15A). In agreement with our results using the HCT116 CTC1F/F
cell line, we found that STN1-/- cells showed a growth defect starting around day 12 after
the addition of Doxy, which is similar in timing to the CTC1-/- cells (Figure 2.15B).
Additionally, we found an accumulation of G2/M cells and a sizable increase in sub-G1
cells 12 days after Doxy addition (Figure 2.16) indicating an increase in cell death and
cell cycle arrest. HeLa cells are p53 deficient, therefore this further supports our idea that
the accumulation of G2 cells following CTC1 deletion is promoted by p53-independent
mechanisms.
In CTC1-/- cells, the G2 arrest is induced in response to the accumulation of
telomeric RPA, which results in ATR activation. We are currently investigating if this
holds true in STN1-/- cell, but preliminary results have suggest that STN1 KO leads to
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similar defects in telomere maintenance and DNA damage signaling. First, RPA-foci
appear to co-localize with telomere-FISH signals (~70%) (Figure 2.17A). Second, we
measured γH2AX localization to RPA-ssDNA as a readout of DDR activation. Similar to
what we saw in CTC1-/- cells, we found increased RPA foci and RPA co-localization with
γH2AX in STN1-/- cells (Figure 2.17B-C). As a more direct measurement of ATR
activation, we measured pRPA32 S33 foci in response to STN1 KO and saw increased
number of nuclei with 3 or more pRPA32 foci, which corresponded to the timing of cell
proliferation decrease and G2 arrest following STN1 removal (Figure 2.17D). These
results suggest that both CTC1 and STN1 are required for the protection of telomeres
from ATR-dependent DNA damage signaling. However, it is still possible that CTC1 and
STN1 have different roles in the binding and localization of the CST complex to different
areas of the genome. For example, at the telomeres CTC1 and STN1 both interact with
TPP1, however only CTC1 appears to bind POT1 [29, 105]. Additionally, STN1, but not
CTC1 or TEN1, was found to interact with different subunits of the CMG helicase to
suppress origin licensing [30]. Thus, additional studies, using the CTC1 and STN1
conditional KO cells and a newly developed TEN1 KO cell line, are needed and will
prove instrumental in our understanding of how CST subunits work together to promote
the diverse functions of the complex as a whole.
2.2F POT1 OVEREXPRESSION PREVENTS RPA-ssDNA AND RESCUES CELL
GROWTH IN CTC1-/- CELLS
POT1 is a ssDNA binding protein and a member of the six-subunit telomere
protection complex, shelterin. One of the primary roles of POT1 is to prevent ATRdependent DNA damage signaling at telomeres through the inhibition of RPA binding to
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G-overhangs [57]. Previous work demonstrated that POT1-OE partially rescues the
telomeric DDR induced following CTC1 knockout (i.e. telomeric RPA and γH2AX) [57].
However, POT1-OE was not able to rescue the elongated G-overhangs, indicating that
POT1 is unable to substitute for CST in telomerase inhibition or C-strand fill-in.
Furthermore, it suggests that endogenous POT1 levels are insufficient to outcompete
RPA for the hyperextended G-overhangs caused by CTC1 deletion. To test the effects of
POT1-OE on cell cycle progression and cell growth, we performed flow cytometry and
growth curve analysis on CTC1-/- cells overexpressing Flag-POT1 (CTC1-/- +POT1)
(Figure 2.18A). In agreement with the previous study, POT-OE prevented RPA as well as
pRPA S33 foci formation in the CTC1-/- cells (Figure 2.18B-C) [57]. Flow cytometry and
cell growth analysis revealed that not only did POT1-OE rescue G2 arrested cells but also
the growth delay associated with CTC1 deletion (Figure 2.19 and 2.20). These results
indicate that increased telomeric RPA-ssDNA, caused by G-overhang elongation, is the
primary cause of decrease proliferation following CTC1 KO and that the non-telomeric
roles of CST do not significantly affect proliferation in unperturbed cells. Furthermore,
they highlight the essential role of POT1 in telomere end protection and indicate that
POT1 exhaustion due in an abundance of telomeric ssDNA has a profound impact on cell
cycle progression and cell growth (Figure 2.21)
2.3 DISCUSSION
One of the major questions we sought to address in this chapter was the
underlying cause(s) of decreased cell proliferation associated with CTC1 removal. In
agreement with previous studies, we find that conditional deletion of CTC1 and STN1
both lead to a partial G2 arrest, which is primarily caused by telomeric RPA-ssDNA [35,
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57]. Unexpectedly, we demonstrate that, while ATR is actively recruited to telomeric
RPA-ssDNA, ATR dependent CHK1 phosphorylation is not detectable in the event of
CTC1 deletion. Instead, we suggest that the primary cause of cell death and checkpoint
activation following loss of CTC1 or STN1 is the accumulation of telomeric RPA due to
POT1 exhaustion.
Our results combined with previous findings indicate that CST plays multiple
functions in the DDR at telomeres. First, it prevents ATR-mediated checkpoint activation
by inhibiting telomerase from hyperextending G-overhangs, leading to RPA-ssDNA
(Figures 2.7 and 2.17) [29, 57]. Second, it promotes ATR-CHK1 signaling once
telomeres are bound by RPA. Despite significant ATR activity at RPA-bound telomeres
in both CTC1-/- and STN1-/- cells, our results suggest that this is insufficient to induce
global CHK1 phosphorylation (Figures 2.5-2.10). While it is possible that low levels of
pCHK1 are present at telomeres but not detectable by Western blot, this seems unlikely,
as a significant portion of the CTC1-/- cells (~25%) contain three or more large RPA foci
and ATR is clearly activated (Figures 2.7-10). Furthermore, attempts to detect pCHK1 at
telomeres were unsuccessful. Previous work also found that replication fork stalling at a
single defined repeat sequence is sufficient to induce detectable ATR-dependent CHK1
phosphorylation [106]. Thus, the significant levels of RPA-ssDNA from elongated Goverhangs in CTC1-/- cells should induce CHK1 phosphorylation, as previously observed
following POT1 deletion in mice and chicken cells [107, 108].
Why CHK1 is not activated in CTC1-/- cells is unclear. Yet, a recent study in
mouse cells showed that CST is required to override POT1b-mediated telomere
protection in S/G2, suggesting that CST may activate ATR-CHK1 signaling at telomeres
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in mice [109]. However, despite the lack of pCHK1, ATR activation from telomere RPAssDNA is sufficient to induce cell cycle arrest, suggesting an alternate ATR pathway is
activated. Determining whether or not these extended G-overhangs are recognized as
DDR and then repaired or shortened, what DDR pathway is activated and the interplay
between POT1 and CST in ATR regulation will require further investigation. However,
our work provides novel insight into ATR-CHK1 signaling at telomeres.
In the absence of CTC1, a previous study found that the G-overhangs because
severely over-extended [57]. We predicted that this incredible amount of ssDNA results
in exhaustion of POT1 and therefore, telomere ends cannot be protected from RPA
localization and ATR activation. Indeed, POT1 overexpression was sufficient to
completely rescue cell growth and block ATR activation following CTC1 removal. Thus,
telomere length regulation/protection not genome-wide replication is the primary
function of CST in unstressed cells.
In summary, we establish CST as a regulator of cell cycle progression by
promoting telomere protection. In the absence of CST, telomeres become over elongated
[57] and thus RPA binds telomeric ssDNA which results in ATR checkpoint activation.
Additionally, overexpression of the shelterin complex component, POT1, can rescue the
cell proliferation and cell cycle defects.
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Table 2.1 Percentage of cells in each cell cycle phase following ATR inhibition.

G1 Phase
CTC1F/F DMSO
CTC1-/- DMSO
CTC1-/-+Flag-CTC1 DMSO
CTC1F/F ATRi
CTC1-/- ATRi
CTC1-/-+Flag-CTC1 ATRi

S Phase
(Edu+)
40.80
15.17
44.20
30.27
16.23
31.90

33.83
40.63
32.97
40.93
45.87
40.07

30

G2 Phase
20.40
30.00
18.23
19.63
20.60
17.03

S Phase
(Edu-)
4.97
14.19
4.60
9.17
17.30
11.00

Table 2.2 Percentage of cells in each cell cycle phase following siATR.
G1 Phase
CTC1F/F siNT
CTC1-/- siNT
CTC1-/-+Flag-CTC1 siNT
CTC1F/F siATR
CTC1-/- siATR
CTC1-/-+Flag-CTC1 siATR

S Phase
(Edu+)
35.23
22.03
30.13
30.77
27.00
26.00

38.83
39.53
40.03
41.17
39.77
42.47
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G2 Phase
22.83
31.63
24.53
23.30
26.97
24.27

S Phase
(Edu-)
3.16
6.75
5.33
4.77
6.27
7.28

Table 2.3 Percentage of cells in each cell cycle phase following siATM.
G1 Phase
CTC1F/F siNT
CTC1-/- siNT
CTC1-/-+Flag-CTC1 siNT
CTC1F/F siATM
CTC1-/- siATM
CTC1-/-+Flag-CTC1 siATM

S Phase
(Edu+)
36.10
21.87
31.87
35.40
20.07
28.07

36.67
38.47
37.70
32.23
35.30
35.50
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G2 Phase
23.10
30.80
24.67
27.40
36.10
29.30

S Phase
(Edu-)
4.16
8.84
5.79
4.93
8.54
7.07

Table 2.4 Percentage of cells in each cell cycle phase following siCHK1.
G1 Phase
CTC1F/F siNT
CTC1-/- siNT
CTC1-/-+Flag-CTC1 siNT
CTC1F/F siCHK1
CTC1-/- siCHK1
CTC1-/-+Flag-CTC1 siCHK1

S Phase
(Edu+)
35.23
22.03
30.13
25.07
16.57
18.13

38.83
39.53
40.03
54.13
56.83
59.33
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G2 Phase
22.83
31.63
24.53
16.53
21.57
17.07

S Phase
(Edu-)
3.16
6.75
5.33
4.27
5.06
5.44

Figure 2.1 Verification of CTC1 KO in HCT116
cells. TAM was added to CTC1F/F and CTC1F/F +
Flag-CTC1 cell lines at day 0 to disrupt CTC1
(CTC1-/-) (A) Western blot of CTC1 KO in HCT116
cells. Representative gel showing days 8, 11, and 13.
Actinin and Ponceau S staining are loading controls.
(B) Agarose gel of truncated CTC1 PCR product in
CTC1-/- and CTC1-/- + Flag-CTC1 samples.
Representative gel showing days 6, 8, 11, and 13.
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Figure 2.2 CTC1 deletion results in proliferation decrease and a partial G2
arrest. (A) Representative growth curve of three independent, biological
replicates. (B-C) Flow cytometry analysis of HCT116 CTC1F/F, CTC1-/-, and
CTC1-/- + Flag-CTC1 cells. (B) Representative histograms from flow cytometry
analysis. Left panel: DNA content (DAPI) versus cell count. Right panel: DNA
content versus replicating cells (EdU+). (C) Percentage of cells in each cell cycle
phase, as indicated. (n=3 independent, biological replicates). Error bars indicate
±SEM. P-values were calculated by one-way ANOVA test (*P ≤0.05, **P ≤0.01,
***P ≤0.001).
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Figure 2.3 CTC1 deletion does not alter replication speed or percentage of
replication events. (A) Image shows representative fibers used for DNA fiber
analysis. Red: IdU labeling. Green: CldU labeling. (B) Dot plot of track length
for elongating forks (Red-Green). Black line and numbers below the graph
indicate the mean length in arbitrary units (AU). n indicates the number of total
tracks scored. (C) Percentage of replication events. Red-only: stalls or
terminations, Green-only: origins fired during second label (CldU), Red-Green:
elongating forks, G-R-G (Green-Red-Green): origins fired in first label (IdU),
R-G-R (Red-Green-Red): terminations. Number of events scored: CTC1F/F: 451,
CTC1-/-: 393, CTC1-/-+Flag-CTC1: 572.
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Figure 2.4 CTC1 deletion is G2 specific and
induces apoptosis. (A) Mitotic index is based on
the levels of phosphorylated Histone H3 as
measured by immunofluorescence. (n=3
independent, biological replicates) Error bars
indicate ±SEM. (B) Fold change of apoptosis as
measured by the Caspase-Glo 3/7 assay. The ATR
inhibitor (5µM, VE-821) was added for 24 h prior
to measurement. (n=3 independent biological
experiments.) Error bars indicate the ±SEM. Pvalues were calculated by an unpaired, two tailed t
test (*P ≤0.05, **P ≤0.01, *** P ≤0.001).
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Figure 2.5 CTC1 deletion does not activate ATR-mediated p53 or
CHK1 phosphorylation or global γH2AX response. (A) Levels of
phosphorylated p53 S15 (p-p53 S15), or CHK1 S317 (pCHK1S317)
and total CHK1 or p53, as indicated. (B) Levels of phosphorylated
CHK1 S345 (pCHK1 S345) and total CHK1 as indicated. (A-B) For
Western blots, Actinin and Ponceau S staining serve as loading
controls. 24 h HU indicates CTC1F/F cells treated for 24 h with 2 mM
HU and were used as a control for activation of the DDR. (C) Left:
Representative images of γH2AX levels at 13 days after addition of
TAM. DAPI: blue, γH2AX: red. Right: Dot plots of mean γH2AX
intensity per nucleus in arbitrary fluorescent units (AFU).
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Figure 2.5 CTC1 deletion does not activate ATR-mediated p53
or CHK1 phosphorylation or global γH2AX response.
(Continued) Black lines and numbers below the graph indicate the
mean AFU and number of nuclei scored (n). 24 h HU sample serves
as a positive control for γH2AX. (n=3 independent, biological
experiments). P-values were calculated by an unpaired, two tailed
Mann-Whitney test (*P ≤0.0001).
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Figure 2.6 CTC1 deletion increases p53/p21, but p53 knockdown
does not suppress the accumulation of G2 cells. (A) Levels of p21, as
indicated. (B-C) Cells were treated with siRNA to a non-targeting
control (siNT) or p53 (sip53) for 72 h prior to collection starting on day
8 after TAM addition. (B) Levels of p53 following siRNA knockdown,
as indicated. * indicates non-specific bands. (C) Percentage of G2/M
cells following siRNA knockdown of p53 (n=3 independent, biological
replicates. For Western blots, Actinin and Ponceau S staining serve as
loading controls. 24 h HU indicates CTC1F/F cells treated for 24 h with
2 mM HU and were used as a control for activation of the DDR. Error
bars indicate the ±SEM. P-values were calculated by an unpaired, two
tailed t test (*P ≤0.05, **P ≤0.01).
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Figure 2.7 Telomeric phosphorylated RPA levels increase in
response to CTC1 KO. (A) Representative images of RPA foci and
telomere FISH signal on day 13 after TAM addition. Cells were preextracted prior to fixation to identity chromatin-bound RPA. DAPI:
blue, RPA32: red, Telomere (TTAGGG3); green. Scale bar represents
5 µm. (B) Percentage of nuclei with three or more RPA foci. (n=3
independent, biological replicates). (C) Percentage of RPA-foci
containing telomere signal in CTC1-/- cells. (n=3 independent,
biological replicates). n indicates the number of total nuclei scored.
Error bars indicate the ±SEM. P-values were calculated by an
unpaired, two tailed t test (**P ≤0.01)
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Figure 2.8 CTC1 deletion results in increased chromatin bound and
telomeric RPA. (A) Representative images of CTC1-/- cells at day 13 after TAM
addition. Scale bar represents 50 µm. (B) Flow cytometry analysis of fold change
in chromatin-bound RPA32 in pre-extracted cells. (n=3 independent, biological
replicates). Error bars indicate the ±SEM. P-values were calculated by an
unpaired, two tailed t test (*P ≤0.05, **P ≤0.01).
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Figure 2.9 Phosphorylated RPA levels are increased in response to CTC1 KO
and are ATR-dependent. (A) Representative images of phosphorylated RPA32
S33 (pRPA) foci on day 13 after TAM addition, as indicated. Scale bar represents
25 µm. (B) Percentage of cells with greater than three pRPA foci. (n=3
independent biological replicates). ATRi: treatment with the ATR inhibitor VE821 for 24 h. n indicates the number of total nuclei scored. Error bars indicate the
±SEM. P-values were calculated by an unpaired, two tailed t test (***P ≤0.001).
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Figure 2.10 RPA localizes with γH2AX DNA damage foci, and ATR is
activated in response to CTC1 KO. (A) Representative images of co-localization
of RPA and γH2AX foci, as indicated. CTC1-/- +HU samples were treated with
HU for 24 h prior to fixation and are used as a control to show the intensity of
γH2AX foci in the presence of global replication stress. Scale bar represents µm.
(B) Percentage of nuclei with greater than 5 co-localizing RPA-γH2AX foci. n
indicates the number of nuclei scored. (n=3 independent, biological experiments).
Error bars indicate the ±SEM. P-values were calculated by an unpaired, two tailed
t test (***P ≤0.001). (C) Levels of total and phosphorylated ATR T1989 (pATR),
as indicated. Actinin and Ponceau S staining are loading controls.
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Figure 2.11 G2 arrest following CTC1 KO is ATR-dependent shown by
ATRi. (A) Western blot analysis of CTC1F/F cells treated with 5 µM ATRi (VE82) for 24 h to confirm ATR inhibition.
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Figure 2.11 G2 arrest following CTC1 KO is ATR-dependent shown by
ATRi (Continued). 2 mM HU was added 2 h prior to collection to induce CHK1
S317 phosphorylation. Actinin and Ponceau S staining serve as loading controls.
(B) Graph of the percentage of G2/M cells at 13 days after TAM addition with
DMSO or ATRi treatment for h. (n=3 independent biological replicates). Error
bars indicate the ±SEM. P-values were calculated by an unpaired, two tailed t test
(**P ≤0.01, ***P ≤0.001). (C) Representative histograms of cell cycle data for
ATRi. Top: DAPI versus cell count. Bottom: DAPI versus EdU signal intensity.
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Figure 2.12 G2 arrest following CTC1 KO is ATR-dependent shown by ATR
knockdown by siRNA. (A) Western blot analysis of CTC1F/F cells treated with
siRNA targeting ATR (siATR) for 72 h prior to collection starting on day 8.
47

Figure 2.12 G2 arrest following CTC1 KO is ATR-dependent shown by ATR
knockdown by siRNA (Continued). Cells were collected on day 11 after TAM
addition and tested for knockdown efficiency. siNT: non-target control. Actinin
and Ponceau S staining serve as loading controls. (B) Graph of the percentage of
G2/M cells following siATR. (n=3 independent, biological replicates). Error bars
indicate the ±SEM. P-values were calculated by an unpaired, two tailed t test (*P
≤0.05, **P ≤0.01). (C) Representative histograms of cell cycle data for siNT and
siATR. Top: DAPI versus cell count. Bottom: DAPI versus EdU signal intensity.
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Figure 2.13 G2 arrest following CTC1 KO is CHK1-independent shown by
CHK1 knockdown by siRNA. (A) Western blot analysis of CTC1F/F cells
treated with siRNA targeting CHK1 (siCHK1) for 72 h prior to collection
starting on day 8. Cells were collected on day 11 after TAM addition and tested
for knockdown efficiency. siNT: non-target control. Actinin and Ponceau S
staining serve as loading controls. (B) Graph of the percentage of G2/M cells
following siCHK1. (n=3 independent, biological replicates). Error bars indicate
the ±SEM. P-values were calculated by an unpaired, two tailed t test (*P ≤0.05,
**P ≤0.01). (C) Representative histograms of cell cycle data for siCHK1. Top:
DAPI versus cell count. Bottom: DAPI versus EdU signal intensity.
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Figure 2.14 G2 arrest following CTC1 KO is ATM-independent shown by
ATM knockdown by siRNA. (A) Western blot analysis of CTC1F/F cells treated
with siRNA targeting ATM (siATM) for 72 h prior to collection starting on day
8. Cells were collected on day 11 after TAM addition and tested for knockdown
efficiency. siNT: non-target control. Actinin and Ponceau S staining serve as
loading controls. (B) Graph of the percentage of G2/M cells following siATM.
(n=3 independent, biological replicates). Error bars indicate the ±SEM. P-values
were calculated by an unpaired, two tailed t test (*P ≤0.05, **P ≤0.01, **P
≤0.001). (C) Representative histograms of cell cycle data for siATM. Top: DAPI
versus cell count. Bottom: DAPI versus EdU signal intensity.
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Figure 2.15 STN1 deletion results in a decrease in cell proliferation. (A) Doxy
was added to HeLa iCas9 sgSTN1 cells at day 0 to disrupt STN1. Western blot of
STN1 KO (+Doxy) on days 12 and 15 after Doxy treatment. Ponceau S staining is
a loading control. (B) Representative growth curve of three independent,
biological replicates.
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Figure 2.16 STN1 deletion results in partial G2 arrest and increased Sub G1
population. (A) Representative histograms from flow cytometry analysis. Top
panel: DNA content versus replicating cells (EdU+). Bottom panel: DNA content
(DAPI) versus cell count. (C) Percentage of cells in each cell cycle phase, as
indicated. (n=2 independent, biological replicates). -Doxy indicates untreated
cells, +Doxy indicates STN1 KO.
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Figure 2.17 STN1 deletion results in increased telomeric RPA foci
and RPA phosphorylation. A) Percentage of RPA foci containing
telomere signal in STN1 KO cells, n indicates the number of total
nuclei scored. (B) Percentage of nuclei with greater than 5 colocalizing RPA-γH2AX foci. n indicates the number of nuclei scored.
(C) Percentage of nuclei with 3 or more RPA foci, n indicates the
number of nuclei scored. (D) Percentage of nuclei with 3 or more
pRPA foci, n indicates the number of nuclei scored. (For all, n=1
biological replicate and were analyzed at 15 Days after doxy
addition).
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Figure 2.18 POT1 over expression rescues RPA and pRPA levels after
CTC1 deletion (A) Western blot of POT1 and Flag-POT1 levels at 11 days
in culture, as indicated. Ponceau S serves as a loading control. (B)
Percentage of nuclei with three or more RPA (B) or pRPA (C) foci 11 days
after CTC1 deletion (n=2 independent biological experiments).

54

Figure 2.19 Over expression of POT1 rescues the CTC1 KO induced
growth defect and cell cycle arrest (A) Representative growth curve of two
independent biological replicates, as indicated. (B) Flow cytometry was used
to assess cell cycle phases, as indicated (n=3 independent biological
replicates). Error bars indicate the ±SEM. P-values were calculated by an
unpaired, two tailed t test (*P ≤0.05, **P ≤0.01, ***P ≤0.001).
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Figure 2.20 Cell cycle profile of CTC1-/- cells with POT1 OE.
(A) Representative graphs from flow cytometry analysis
showing DNA content (DAPI) versus replicating cells (EdU+).
(B) Representative histograms from flow cytometry analysis
showing DNA content versus cell count.
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Figure 2.21 Model of telomere damage signaling after CTC1 deletion with or
without POT1 OE. POT1 prevents telomeric RPA binding and thus inhibits
ATR activation at telomeres. In the absence of CTC1 (CTC1-/-), the telomeric Goverhand is hyperextended, leading to the exhaustion of POT1 in the cell and
telomeric RPA binding. This in turn leads to ATR localization and G2 arrest.
However, when POT1 is overexpressed in the absence of CTC1 (CTC1-/-+POT1),
the G-overhangs are coated by POT1, blocking RPA binding and G2 arrest.
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CHAPTER 3
CST IS A NOVEL REGULATOR OF TOPBP1 AND THE ATR-CHK1 SIGNALING
PATHWAY
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3.1 INTRODUCTION
As seen in previous studies and in Chapter 2, CTC1 or STN1 KO results in Goverhang elongation to the point that endogenous POT1 is insufficient to protect the
ssDNA. In mammals, POT1 prevents RPA from binding the G-overhang, which in turn
suppresses ATR activation and unwanted “repair” of the telomeres by HR. ATR is the
predominant kinase which responds to ssDNA damage genome-wide. RPA-bound
ssDNA serves as a platform for localization of ATR to the damage site through
interaction with ATRIP. However, localization alone is not sufficient for ATR activation.
To date there are two known activators of ATR, ETAA1 and TopBP1. Whether ATR
activation occurs via ETAA1 versus TopBP1 is dependent on cell cycle phase and the
presence of DNA damage. ETAA1 plays a primary role in ATR activation during normal
DNA replication and mitosis, and is suggested to play only a minor role in the DDR
(30139873 and 30755469). On the other hand, TopBP1 is essential for activation of ATR
in response to ssDNA damage [12].
For TopBP1 localization to ssDNA damage, it engages the 9-1-1 complex at dsssDNA junctions [2, 16, 17]. TopBP1 interacts with and activates ATR in a mechanism
which is both necessary and sufficient for stimulating ATR-ATRIP [12]. Once activated,
ATR then phosphorylates a number of downstream substrates. In particular, ATR
phosphorylates CHK1 at residues S317 and S345 activating this effector kinase [19, 20].
CHK1 then phosphorylates additional effectors which contribute to G2 arrest as well as
intra S-phase inhibition of origin firings [110-112]. Although ATR is activated and
induces a partial G2 arrest in CTC1-/- cells (Figures 2.7-11), CHK1 is not activated.
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Therefore, we were interested to see if TopBP1-dependent ATR signaling to CHK1 is
defective in response to exogenous stress.
3.2 RESULTS
3.2A CTC1 KO LEADS TO DECREASED LEVELS OF TopBP1
Since TopBP1 recruitment is independent of ATR recruitment to DNA damage,
we examined whether defects in TopBP1 recruitment and protein expression could
explain why CHK1 is not phosphorylated (Figure 2.5) despite significant levels of RPAssDNA and ATR activation after CTC1 deletion (Figures 2.7-2.9). TopBP1 protein levels
were measured at days 8, 11 and 13 following TAM addition (Figure 3.1). Surprisingly,
we observed a decrease in TopBP1 following conditional CTC1 KO starting at day 11
after TAM addition. These findings are significant as the timing of TopBP1 decline
corresponds to the increase in RPA-ssDNA and accumulation of G2 cells following
CTC1 removal. This suggested to us that ATR-mediated CHK1 signaling could be
defective due to decreased cellular and chromatin-bound TopBP1. We also examined the
levels of the other major ATR activator ETAA1 and found that it was also decreased in
the CTC1-/- cells (Figure 3.1). Since ETAA1 appears to play a minor role in ATRmediated CHK1 activation following DNA damage, it is unclear how this might affect
checkpoint signaling. However, it is possible that decreased ETAA1 could contribute to
changes in cell cycle progression. We next examined whether decreased TopBP1 was due
to changes in gene expression. We performed qPCR to measure TopBP1 mRNA levels
but did not observe any significant changes at day 8 and only minor changes at days 11
and 13 that were not statically significant, suggesting that decreased protein stability and
not gene expression is likely responsible for the changes in TopBP1 (Figure 3.1D).
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3.2B CTC1 PROMOTES ATR-MEDIATED CHK1 SIGNALING FOLLOWING
EXOGENOUS REPLICATION STRESS THROUGH TopBP1
Since TopBP1 is important for ATR-CHK1 activation, we hypothesized that CST
promotes CHK1 phosphorylation in the presence of exogenous replication stress by
stabilizing TopBP1. This would be consistent with previous findings demonstrated that
shRNA depletion of TopBP1 results in reduced pCHK1 S317/S345 following replication
stress [113]. To test our hypothesis, we measured CHK1 phosphorylation in cells
following treatment with HU, which is known to induce global replication fork stalling,
create excess ssDNA and activate the ATR-CHK1 pathway [114]. Cells were treated with
HU for 2 h before collection to generate ssDNA but not cause fork collapse and DSBs
[115]. Phosphorylation of CHK1 and γH2AX staining were then assessed by Western
blot and IF, respectively (Figure 3.2 and 3.3). In line with our hypothesis, we observed a
decrease in the levels of pCHK1 S317/S345 and γH2AX in CTC1 deleted cells compared
to controls.
To see whether we could rescue pCHK1 levels, Flag-tagged TopBP1 was
exogenously expressed in CTC1-/- and control cell lines at day 8 after TAM addition. At
day 11, cells were treated with HU for 2 h and then collected for Western blot analysis.
Transfection with exogenous TopBP1 resulted in similar levels of TopBP1 in the
CTC1F/F, CTC1-/- and CTC1-/-+Flag-CTC1 cells (Figure 3.4A). pCHK1 S317 was then
measured as a readout of ATR-dependent CHK1 activation (Figure 3.4A). While CHK1
phosphorylation was inhibited in the CTC1-/- cells, we found that expression of
exogenous TopBP1 rescued CHK1 phosphorylation in response to HU treatment. A
possible explanation for the decreased pCHK1 is that it arises from the lower number of
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S-phase cells following CTC1 KO (Figure 2.2B). To exclude this possibility, we
determined the number of S-phase cells with and without expression of Flag-TopBP1
(Figure 3.5). In both cases, the number of S-phase cells is decreased in CTC1-/- cells,
however, pCHK1 S317 is rescued with TopBP1 expression after HU treatment. These
findings strongly suggest that the lower level of S-phase cells do not account for the
decreased levels of pCHK1 observed in the CTC1-/- cells after HU treatment.
Interestingly, while addback of TopBP1 rescued pCHK1 following replication stress, it
did not rescue global pCHK1 in CTC1-/- cells in the absence of HU treatment. Thus,
restoration of TopBP1 levels alone is not sufficient to rescue ATR-CHK1 signaling
arising from telomere-bound RPA and additional factors likely contribute to the telomere
DNA damage response in the absence of CST.
3.2C STN1 KO PREVENTS CHK1 PHOSPHORYLATION DUE TO
DECREASED TopBP1 LEVELS IN THE CELL
To further validate the role of CST in TopBP1 expression and ATR-CHK1
signaling, we assessed TopBP1 and pCHK1 levels in HeLa iCas9 STN1 KO cells. In
agreement with the experiments in CTC1-/- cells, we found that STN1 deletion results in
severe loss of TopBP1 (Figure 3.6). Furthermore, CHK1 phosphorylation is absent in
untreated cells, and upon HU induction, CHK1 is not activated in STN1-/- cells. Unlike
CTC1 deletion, STN1 KO also showed decreased levels of total CHK1 (Figure 3.6). The
mechanism behind this still unclear but could be due to differences in the cell type used
or possible non-overlapping functions of CTC1 versus STN1. Overall, these results
indicate that both CTC1 and STN1 are required to regulate TopBP1 and fully activate the
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ATR-CHK1 pathway in response to genome-wide replication stress (Figure 3.7). These
results could in part explain how CST promotes recovery from replication stress.
3.3 DISCUSSION
Here, we further investigated the surprising results from Chapter 2 in which ATR
activation does not result in CHK1 phosphorylation after CTC1 deletion. Upon further
analysis, we discovered that CST regulates the ATR activator TopBP1 and that removal
of CTC1 or STN1 leads to a substantial decrease in CHK1 phosphorylation following
global replication stress. Together, these findings highlight an unanticipated function of
human CST in maintaining genome stability through the regulation of CHK1
phosphorylation.
As seen in Chapter 2, POT1 overexpression was able to rescue the G2 arrest in
CTC1-/- cells (Figure 2.19). In a similar vein, we propose that CST could both stabilize
TopBP1 and override telomere protection pathways to induce “repair” or shortening of
the G-overhang. It is also possible that hyperextension of the G-overhang activates
protection mechanisms that lead to TopBP1 degradation as a means to prevent
recognition of the RPA-coated G-overhang as recombination intermediates.
In regard to genome-wide ATR activation following replication stress, our results
determined that regulation of TopBP1 by CST contributes to ATR-CHK1 signaling.
Unlike untreated CTC1-/- cells, with HU-induced fork stalling, CHK1 activation is fully
rescued by overexpression of TopBP1 (Figure 3.4). In the event of genome-wide
replication stress, decreased TopBP1 levels short-circuit TopBP1-dependent ATR
activation (Figure 3.7). However, while ATR was active at telomeres (i.e. pRPA), ATR-
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CHK1 signaling was compromised not only due to decreased TopBP1 levels, but also
some yet undiscovered mechanism.
TopBP1 is integral to both checkpoint activation and DNA replication origin
firing [116], so why is DNA replication and origin firing not inhibited in these cells? We
propose that it is due to the decreased but not complete absence of TopBP1 (Figure 3.1).
In this case, while there is enough TopBP1 for origin activation, these levels are
insufficient to fully activate ATR-mediated CHK1 signaling. This suggests that it may be
possible to separate TopBP1 functions through regulating its protein expression and
would also explain why pCHK1 levels are decreased but not absent following global fork
stalling in the CTC1-/- cells. Furthermore, it implies that TopBP1 is regulated through
multiple pathways.
While the mechanism of ATR activation by TopBP1 has been closely examined,
how TopBP1 levels are regulated remains poorly understood. Previous work has shown
that TopBP1 is post-transcriptionally regulated by two E3 ubiquitin ligases, UBR5 (also
known as EED1 and hHYD) and HUWE1 (also known as HECTH9 and MULE) [117119]. Interestingly, TopBP1 when not chromatin associated is targeted for degradation by
the ubiquitin ligase, HUWE1 [117]. This protection is at least partly facilitated by the
transcriptional repressor Miz1. In a similar manner, CST could stabilize TopBP1 by
recruiting it to the chromatin. As to the mechanism of CST recruitment to stalled forks,
we recently showed that CST interacts with the MCM2-7 helicase [30]. Thus, CST could
be recruited to stalled forks by MCM2-7 and then recruit TopBP1 to prevent degradation,
stimulating ATR-mediated CHK1 phosphorylation. However, whether CST directly or
indirectly stabilizes TopBP1 will require further studies.

64

In addition to TopBP1, ATR can also be activated by ETAA1. However, several
studies suggest that TopBP1 is the dominant pathway for ATR-CHK1 activation
following replication stress [10, 120]. Recent work from the Cortez lab showed that, in
HCT116 cells, deletion of the AAD of ETAA1 did not inhibit ATR activation. Yet,
attempts to delete the AAD of TopBP1 resulted in cell death, indicating that, at least in
HCT116 cells, TopBP1 is the major activator of ATR [14]. Accordingly, it is unlikely
that ETAA1 could compensate for decreased TopBP1. In addition, we find that ETAA1
levels are also decreased after CTC1 KO, suggesting this potential secondary pathway is
not even available for ATR-mediated CHK1 activation (Figure 3.1). Why ETAA1 levels
are decreased following CTC1 deletion is unclear. However, it is possible that TopBP1
and ETAA1 are regulated through similar mechanisms. In summary, we establish CST as
a regulator of ATR-CHK1 signaling in response to global replication stress through
maintenance of TopBP1 levels. While further studies are essential to delineate the
mechanism by which CST regulates TopBP1 levels, this is a ground breaking first step in
understanding the regulation of TopBP1 activity.
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Figure 3.1 CTC1 deletion leads to decreased TopBP1. Western blots of soluble
(A), chromatin (B), and (C) whole cell extractions at days 8, 11, and 13, as
indicated. Ponceau S serves as a loading control for total protein. α-Tubulin and
H3 serve as controls for the soluble and chromatin extracts, respectively. *
Indicates non-specific bands. (D) Graph of the fold change in TopBP1 mRNA
levels at days 8, 11, and 13 following TAM addition in HCT116 cells. CTC1-/-,
and CTC1-/-+Flag-CTC1 fold change is normalized to the CTC1F/F sample on
each day. Statistical analysis by t test did not find any samples that reached a pvalue <0.05. (n=3 independent, biological experiments).
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Figure 3.2 CTC1 promotes ATR-CHK1 signaling following
HU treatment. (A-B) Western blots of pCHK1 S317 (A) or
pCHK1S345 (B) from whole cell lysates after treatment with 2
mM HU for 2 h, as indicated. Quantification of pCHK1 signal
intensity is indicated above the gel. Total CHK1 levels were used
to normalize the pCHK1 signal.
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Figure 3.3 CTC1 promotes ATR signaling through γH2AX
following HU treatment. Cells were treated with 2 mM HU for
24 h at 13 days after TAM addition. (A) Representative images of
γH2AX signal. DAPI: blue, γH2AX: red. (B) Dot plots of mean
γH2AX intensity per nucleus in arbitrary fluorescent units (AFU).
Black line and numbers below the graph indicate the mean AFU
(n=3 independent, biological replicates). P-values were calculated
by an unpaired, two-tailed Mann-Whitney test (****P ≤0.0001).
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Figure 3.4 TopBP1 promotes ATR-CHK1 signaling in the
absence of CTC1. Cells were transfected with pcDNA3-TopBP1
on day 8 and then collected on day 11. Western blot analysis of
TopBP1 and pCHK1 S317 in whole cell lysates. For HU treated
samples, cells were treated with 2 mM HU for 2 h just prior to
collection. 24 h HU indicates CTC1F/F cells treated for 24 h with 2
mM HU and were used as a positive control for pCHK1. Total
CHK1, Actinin and Ponceau S serve as loading controls.
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Figure 3.5 Exogenous TopBP1 expression does not
increase the number of S-phase cells in CTC1-/cells. Cell cycle profile analysis at 13 days after TAM
addition with or without expression of exogenous
Flag-TopBP1. (n=3 independent, biological
replicates). Error bars indicate the ±SEM. P-values
were calculated by an unpaired, two tailed t test (*P
≤0.05, **P ≤0.01, ***P ≤0.001).
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Figure 3.6 STN1 promotes TopBP1 stability
and ATR-CHK1 signaling following HU
treatment. Western blots of TopBP1 and
pCHK1 S345 at 15 days after iCas9 deletion of
STN1 (+Doxy). Samples were treated with or
without 2 mM HU treatment for 2 h, as
indicated. CHK1 and Ponceau S are loading
controls.
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Figure 3.7 Model of CTC1 function in ATR-CHK1 activation
following fork stalling. Following RPA binding, ATRIP-ATR and the
9-1-1 complex are recruited to the ssDNA damage. In the presence of
CTC1 (CTC1F/F), TopBP1 is then recruited for ATR-CHK1 activation
and G2 arrest (left). However, when CTC1 is absent (CTC1-/-), TopBP1
is destabilized leading to inhibition of CHK1 phosphorylation (right).
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CHAPTER 4
STRUCTURE AND FUNCTIONAL ANALYSIS OF CTC1
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4.1 INTRODUCTION
CTC1 promotes accurate and successful telomere replication (Chapter 2), and is a
novel regulator of the ATR-CHK1 pathway (Chapter 3). However, it is unclear whether
CST acts to rescue hyper-elongated G-overhangs to inhibit telomeric DNA damage
signaling. Furthermore, little is still known about CST structure and how different
domains affect cellular function.
Before the recent discovery of the cryo-EM structure of CST, CP patient
mutations were used to try to separate different functions of CST through
structural/function analysis. CTC1 mutations that cause CP have been identified across
the CTC1 gene with the majority ocurring within the OB-fold domains [58]. Some
phenotypes of these mutants overlap, such as the ability to interact with pol α, which is
essential for CST stimulation of pol α activity. However, other functions of CTC1 are
more localized to specific areas, such as the C-terminus which is important for CTC1STN1 interaction, or OB-B and D which are important for preventing telomere
elongation [93]. Engaging multiple OB-folds allows for dynamic and high affinity
binding, and is proposed to facilitate “hand-off” of the DNA to other processing proteins
depending on the needs of the cell [27]. For instance, after telomeres are elongated, CST
promotes the inhibition of telomerase and stimulates pol α activity for fill-in of the Cstrand to create duplex DNA and shorten the length of the G-overhang. This allows
shelterin binding, t-loop formation, and protection of the telomere ends [58]. Since CST
was shown to reverse resection at DSBs, we hypothesize that it could also do so at hyperelongated telomeres [31, 121].
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Thus far, we show that after CTC1 deletion, the telomere ends become over
elongated and bound by RPA, leading to ATR localization to telomeres and activation of
the DDR. Additionally, CTC1 regulates the ATR-CHK1 pathway by stabilizing TopBP1
levels in the cell. However, it is unclear whether CTC1 can also rescue these phenotypes
to prevent genome instability. Therefore, we investigated the roles of CTC1 in activating
and potentially reversing the telomeric DDR through a two-pronged approach. First,
CTC1 was transiently expressed after these initial defects arise in CTC1-/- cells to
determine whether CTC1-/- phenotypes can be rescued. Second, by using different CTC1
constructs with OB-fold mutations to assess the essential domains necessary for its
various roles in promoting genome stability.
4.2 RESULTS
4.2A TRANSIENT CTC1 EXPRESSION PARTIALLY RESCUES RPA-γH2AX
During normal telomere replication, CST stimulates pol α activity to promote Cstrand fill-in which provides a short G-overhang for POT1 to bind and inhibit ATR
signaling. Previous studies and work presented here demonstrate that conditional deletion
of CTC1 prevents C-strand fill-in resulting in over extended G-overhangs [37]. The
endogenous POT1 pool is then exhausted and RPA accumulates on the telomeric ssDNA,
thus promoting ATR activation and G2 arrest (Chapter 2). Since CST has a preference for
G-rich sequences, we asked whether addback of CTC1 promotes pol α localization to the
telomeres for C-strand fill-in to reverse the phenotypes of over elongated G-overhangs
and ATR activation. We hypothesized that re-expressing CTC1 after the appearance of
these phenotypes might reverse the over-extension of the G-overhang and rescue CTC1
KO related defects. CTC1 deletion results in decreased proliferation and partial G2 arrest
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beginning 9 days after TAM treatment. Therefore, we transiently expressed pcDNA3Flag-CTC1 for 48 h starting at 9 days after CTC1 KO. Flag-CTC1 expression was
confirmed by IF with a transfection efficiency of about 30% (Figure 4.2). Flow cytometry
analysis indicated that G2 arrest following CTC1 addback did not rescue the partial G2
arrest in CTC1-/- cells. Interestingly, addback of Flag-CTC1 resulted in increased G2
arrest and sub G1 population with both CTC1F/F and CTC1-/- backgrounds (Figure 4.2B).
A possible explanation of this could be that CTC1 is needed in stoichiometric amounts to
maintain the balance of genome stability.
Since CTC1 deletion results in over-elongated telomeres are bound by RPA and
activate ATR signaling, we assessed pRPA and RPA-γH2AX colocalization by IF. We
hypothesized that CTC1 addback could promote C-strand fill-in to prevent RPA binding
and ATR signaling at telomeres. However, we found no significant changes in nuclei
with 3 or more pRPA foci (Figure 4.8A), indicating that ATR is still activated. We next
looked to see if CTC1 addback rescued telomeric RPA-γH2AX. We found a significant
decrease in nuclei with 3 or more RPA-γH2AX foci after Flag-CTC1 expression (Figure
4.8B). While significant, it was not completely rescued to CTC1F/F levels. Although the
RPA-γH2AX rescue is modest, this is an exciting result considering only a small subset
of cells express Flag CTC1 (Figure 4.1). In future studies with this system, we will
increase the transfection efficiency of the Flag-CTC1 construct to determine if this
further decreases RPA-γH2AX foci. These preliminary results suggest that re-introducing
CTC1 in CTC1-/- cells may rescue telomeric DDR through promoting C-strand fill-in and
rescue of the over-extended G-overhangs.
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4.2B CTC1 OB-FOLDS B-F ARE NECESSARY FOR PROPER CELL
PROLIFERATION AND CELL CYCLE PROGRESSION
The use of OB-folds allows for high affinity and dynamic binding to different
DNA substrates by CST [27-29, 62]. One explanation of this dynamic binding capability
is that CTC1 has a core site that tightly binds G-rich ssDNA and then also secondary sites
which can engage longer stretches of ssDNA [58]. Therefore, we hypothesize that the
dynamic binding and/or high affinity binding of CTC1 to ssDNA is required for the
localization of CST to telomeres or sites of genome-wide DNA damage or used in
protein-protein interactions. To understand the role of the different OB-folds for CST
function, we used four HCT116 CTC1-/- cell lines stably expressing CTC1 mutants with
deletions of different OB-folds, which were graciously provided to us by Dr. Xuyang
Feng. These mutants were created prior to the release of the cryo-EM structure of CST,
using the predicted locations of the CTC1 OB-folds but align closely with the OB-fold
predictions from the structure [58]. As seen in figure 4.4, these mutants target OB-folds
B, C, D, and E/F as indicated. Like the HCT116 CTC1F/F+Flag-CTC1 cell line used
previously, all four mutant constructs are Flag-tagged to allow easy detection. We first
analyzed the expression of the ΔOB-mutants by western blot (Figure 4.5A) and found
that ΔOB-C, ΔOB-D, and ΔOB-E/F expressed at levels similar to full length Flag-CTC1.
ΔOB-B levels, however, were lower than the others but are likely comparable with wild
type CTC1 levels (see Figure 2.1).
After confirming expression of the ΔOB-mutants, we assessed cell proliferation
and cell cycle progression in cells expressing CTC1 OB-fold mutants. We found that
ΔOB-B and ΔOB-C did not rescue cell proliferation following CTC1 deletion. On the
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other hand, ΔOB-D and ΔOB-E/F partially rescued cell proliferation. However, none of
the mutants were able to rescue cell growth to levels of cells expressing full length FlagCTC1 (Figure 4.5B). These results indicate that full length OB-C is essential for proper
cell proliferation and OB-B could be important in normal cell growth. These findings
suggest that the ability of CTC1 to properly promote genome stability is dependent on the
presence of OB-folds B-F. However, we acknowledge that expression of the ΔOB-B
mutant is lower than other rescue cell lines, and may not be at levels sufficient to restore
function. Next, we examined the cell cycle by flow cytometry (Figure 4.6). Our
preliminary results indicate that OB-B-F are all essential to prevent a partial G2 arrest
(Figure 4.7). This suggests that the different OB-folds of CTC1 contribute to the
inhibition of ATR-dependent G2 arrest.
4.2C CTC1 OB FOLDS C-F ARE DISPENSIBLE FOR TOPBP1 REGULATION
After conditional KO of CTC1, we observed a significant decrease in levels of the
ATR-activating protein, TopBP1 (Figure 3.1). To test whether the OB-fold mutants were
able to rescue TopBP1 levels in the CTC1 KO cells, we assessed TopBP1 levels in
untreated and 2 h 2 mM HU treated cells. We found that expression of ΔOB-C, ΔOB-D,
or ΔOB-E/F was sufficient to rescue TopBP1 expression to levels comparable to those in
the CTC1F/F and CTC1-/-+Flag-CTC1 (Figure 4.5) suggesting that the C-terminal domains
are not involved in stabilizing TopBP1 levels.
4.3 DISCUSSION
CST promotes genome stability both at the telomeres and genome wide after
DNA damage. Here, we were interested in whether CTC1 can rescue G-overhang
elongation and began characterizing the roles of CTC1OB-folds in cell proliferation and
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stabilizing TopBP1. In these preliminary studies, we found that CTC1 may promote Cstrand fill-in of over elongated telomeric ssDNA reducing the amount of RPA-ssDNA
and ATR-dependent DDR. Overall, this suggests that CTC1 may promote the protection
of telomeres even after they have become over elongated through misregulation of
telomerase activity. Future studies will assess whether CTC1 addback can rescue TopBP1
levels and ATR-CHK1 activation as well as whether specific OB-fold domains are
required for the rescue of these phenotypes.
Through structural analysis of the different roles of CTC1 in genome stability, we
saw that OB-folds B-F are essential for proper progression through the cell cycle and
normal cell proliferation. OB-D-F were able to partially rescue cell growth, however this
was still inhibited compared to CTC1F/F. Additionally, we assessed the effects of OBfolds B-F on TopBP1 stability and found that OB-folds C-F are dispensable for the
regulation of TopBP1. This result is surprising in particular in regard to the ΔOB-E/F
mutant. OB-E contains the interacting site with the first STN1 wHTH domain, and as we
saw previously, not only CTC1, but also STN1 deletion results in decreased TopBP1
expression. A few explanations for why these OB-folds are not necessary to maintain
TopBP1 levels are as follows. First, CTC1-OB-G also interacts with STN1 through its
singular OB-fold, and this may be sufficient to maintain CST complex formation.
Second, CTC1 and STN1 may have separate mechanisms by which they maintain
TopBP1 stability. Future work will continue to fine tune our understanding of the relation
between CTC1 structure and function by examining CP patient mutations in studies
similar to that done with the CTC1 OB-fold mutants.
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Figure 4.1 CTC1 addback transfection efficiency at day 11 in CTC1-/cells. (A) Representative images of CTC1F/F and CTC1-/- cells after 48 h
transfection with pcDNA3-Flag-CTC1. (B) Percentage of GFP positive cells,
representing pcDNA3-Flag-CTC1 transfection efficiency. (n=1 biological
replicate).
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Figure 4.2 Flag-CTC1 transfection does not rescue CTC1 KO induced G2
arrest. (A) Representative histograms of flow analysis. Top panel: representative
histograms from flow cytometry analysis showing DNA content versus cell
count. Bottom panel: DNA content (DAPI) versus replicating cells (EdU+). (B)
Cell cycle profile analysis at 11 days after TAM addition with 48 h exogenous
pcDNA3-Flag-CTC1 (n=1 independent, biological replicate).
81

Figure 4.3 Exogenous CTC1 addback partially rescues γH2AX-RPA
foci. (A) Percentage of nuclei with three or more pRPA foci 11 days after
CTC1 KO with 48 h transfection. (B) Percentage of nuclei with greater
than 3 co-localizing RPA-γH2AX foci. (n=3 independent, biological
experiments). Error bars indicate the ±SEM. P-values were calculated by
an unpaired, two tailed t test (*P≤ 0.05, **P ≤ 0.01)
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Figure 4.4 Schematic of ΔOB-Mutants in HCT116 CTC1-/- cells. For ΔOB-B
amino acids 220-335, are deleted (all of OB-B). For ΔOB-C, aa 341-412 are
deleted (the N-terminal portion of OB-C). For ΔOB-D, aa 609-702 are deleted (the
majority of OB-D). For ΔOB-E/F, aa 851-921 are deleted (the C-terminus of OB-E
and N-terminus of OB-F).
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Figure 4.5 CTC1 OB-fold mutants partially rescue the CTC1 KO cell
proliferation defect. (A) Western blot of Flag-tagged CTC1 WT and CTC1 OBMutants in HCT116 cells at day 11, as indicated. Ponceau S staining is a loading
control. (B) Representative growth curve of CTC1 KO with Flag-CTC1 and FlagOB-Mutants.
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Figure 4.6 Cell cycle profile of CTC1-/- cells with OB-Mutant expression.
Representative graphs from flow cytometry analysis. Left panel: DNA content
(DAPI) versus replicating cells (EdU+). Right panel: representative histograms
from flow cytometry analysis showing DNA content versus cell count.
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Figure 4.7 Addback of ΔOB-Mutants have limited effect on G2 arrest
in CTC1-/- cells. Percentage of cells in each cell cycle phase, as indicated.
(n=1 biological replicate).
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Figure 4.8 TopBP1 is partially rescued by expression of OB-fold
mutants. (A) Western blot analysis of TopBP1 and pCHK1 S317 in
whole cell lysates treated with 2 mM HU for 2 h just prior to collection.
(B) Western blot analysis of TopBP1 in whole cell lysates. For A and
B, extracts were collected at 11 days after TAM addition. Actinin and
Ponceau S serve as loading controls.
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CHAPTER 5
GENERAL CONCLUSIONS
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Our understanding of the roles of CST has evolved over the years from its first
discovery in yeast cells over 40 years ago [60, 61]. In S. cerevisiae, CST binds to the Goverhang and plays a primary role in end protection [122, 123]. However, in higher
eukaryotes shelterin is the primary telomere capping protein[46]. For many years it was
thought that CST had been lost in higher eukaryotes and replaced with the shelterin
complex. However, in 2009, CST was discovered in plants and mammalian cells. In
higher eukaryotes, STN1 and TEN1 share homology with their yeast counterparts,
however, CTC1 and Cdc13 do not share homology [59, 62, 63]. This difference between
the two CST complexes could possibly explain the more diverse roles of CST in higher
eukaryotes versus S. cerevisiae. CST has conserved roles in inhibition of telomerase
over-extension of the telomeres and in promoting C-strand fill in [45]. However,
numerous studies have found that CST evolved additional telomere and non-telomeric
functions. For instance, it promotes telomere replication through melting of secondary
structures (G4s) [27, 54]. Genome-wide, CST can rescue replication fork stalling arising
from endogenous and exogenous stresses, and aids in regulation of origin licensing [34,
45, 53]. Other evidence also indicates that CST is important for maintaining genome
stability as CST depletion leads to anaphase bridges, chromatin cohesion loss, and
micronuclei which may arise from telomeric or non-telomeric damage [63, 65].
Therefore, our main question was whether CST functions primarily at the telomere,
genome-wide, or a combination of the two in order to prevent genome instability.
To get at this question we analyzed genome-wide DNA replication using DNA
fiber analysis and found that CTC1 deletion does not affect replication speed, suggesting
that CST has a more specialized role in promoting genome stability. A previous study
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found that CTC1 deletion results in over-elongation of the G-overhang by kilobases in
length [57]. Therefore, we wondered if the cell cycle arrest we see with CTC1 or STN1
deletion is instead due to the telomere defects. By overexpressing POT1 we found that
the CTC1 KO induced growth defects were completely rescued. Under homeostatic
conditions, telomerase adds ~10 telomeric hexanucleotide repeats before CST inhibits its
activity and stimulates polα fill-in of the C-strand [55, 56]. However, we were curious as
to whether CST can also work with polα to fill in on a much larger substrate, like those
we see after CTC1 deletion. Our preliminary results suggest that adding back CTC1 after
the telomeres have become elongated can partially rescue the over-elongated ssDNA.
While further studies are required, this suggests that not only can CST prevent telomere
over-elongation, but may also rescue consequences of telomere length regulation.
Therefore, our work indicates that the genome instability we see in the absence of CST is
likely due to dysregulation of the telomeres.
The overexpression of POT1 also rescued levels of telomeric RPA, therefore, we
asked if the DDR goes through the canonical ATR pathway. ATR is the primary
responder to ssDNA damage, and is localized to these damage sites through the
interaction of ATRIP-ATR with RPA [2, 3, 8, 12]. However, this is not sufficient to fully
activate ATR. TopBP1 is one of the two known ATR activating proteins and is
independently localized to damage sites through its interaction with the 9-1-1 complex
[16, 17]. After ATR is activated by TopBP1, it signals downstream to CHK1 and p53
[20-22]. We found that ATR is indeed localized to telomere-bound RPA and is
responsible for the cell cycle defect we observed. However, we were surprised to find
that ATR does not signal through the canonical ATR-CHK1 pathway. This suggests that
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in response to long stretches of telomeric ssDNA, ATR doesn’t signal to CHK1, but
activates an unknown pathway. In support of this, the cell cycle arrest is ATR but not
CHK1 or p53 dependent.
Since the canonical ATR-CHK1 pathway is not activated and is dependent on
TopBP1 activation of ATR, we asked whether TopBP1 levels are compromised. TopBP1
is essential for cell survival, therefore we were shocked to find that TopBP1 levels are
severely decreased in response to CTC1 or STN1 KO. We presumed that reintroducing
TopBP1 would induce ATR-CHK1 signaling in response to over-elongated telomeres.
However, we were surprised to find that even with sufficient levels of TopBP1, ATR was
still unable to phosphorylate CHK1. This suggests that TopBP1 is not required to activate
ATR in response to telomere damage and instead is activated and signals through a
previously unknown pathway.
Our next question was whether the ATR-CHK1 pathway is also dysfunction in the
event of genome-wide replication stress due to the decrease in TopBP1 stability or if this
is a telomere specific response. Therefore, we induced replication for stalling resulting in
stretches of ssDNA which we presumed would result in robust ATR-CHK1 signaling.
However, we were surprised to find that CST also affects ATR signaling in response to
genome wide replication stress by regulating TopBP1 stability. Unlike at the telomeres,
restoring TopBP1 levels is sufficient to induce CHK1 phosphorylation in the absence of
CST. Therefore, CST is essential for the activation of the canonical ATR-CHK1
signaling pathway in response to global DNA replication stress.
Our results suggest that there may be different pathways that ATR activates to
respond to telomeric versus global DNA damage. This could possibly be due to the
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limited substrates for the 9-1-1 complex to bind. 9-1-1 localizes to ds-ssDNA junctions,
and the telomere, because it is the chromosome end, there is only one such junction to
respond to kilobases worth of ssDNA. Another possibility is that shelterin binding blocks
9-1-1 localization [17]. These collectively could explain why even if we rescue TopBP1
levels, it would not affect telomeric ATR-CHK1 signaling because it is not involved in
the telomeric ATR activation. Thus, there may be a yet to be discovered signaling
cascade that is activated by ATR in response to telomere damage.
OB-folds function in protein-DNA and protein-protein interactions and proteins
with multiple OB-folds can bind dynamically to their substrates. Therefore, we wondered
how the multiple OB-fold domains of CTC1 affect its function. To this end we used OBfold mutants with different domains deleted to asses cell proliferation and cell cycle
progression. Our results indicate that each of the OB-folds is at least partially required for
proper cell growth. Mutations in CTC1 underlie two telomeropathies, CP and DKC, with
many of them falling within OB-fold domains. Therefore, future studies assessing the
importance of these different domains will deepen our understanding of telomeropathies
and the structure dependent functions of CST.
Overall, our results uncovered a novel link between the telomeric and nontelomeric roles of CST. For years, the different roles of CST have been viewed as two
separate entities: telomere protection and genome-wide replication. However, this work
indicates an essential link between the two. Unlike ATM and DNA-PK, ATR is essential
in proliferating cells [1]. ATR promotes repair in the event of genome-wide replication
stress, but also in responding to telomere over-elongation [1]. Our discovery that CST is
essential to fully activate ATR not only in response to telomeric ssDNA, but also after
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replication stress by stabilizing TopBP1 levels underscores the importance of CST in
promoting genome stability. By manipulating these different, but synergistic roles of
CST, we may be able to target the complex in diseases that hijack the DDR. The DDR is
often dysregulated in cancer cells, and therefore they are reliant on maintaining a balance
of continuous proliferation while preventing catastrophic levels of genome instability.
Therefore, CST is a possible target which can tip the balance by possibly synergizing
with ATR inhibitors to increase genome instability to a level unsustainable by cancer
cells.
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CHAPTER 6
MATERIALS AND METHODS
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Cell Culture
HCT116 CTC1F/F and CTC1F/F+Flag-CTC1 cells were generously provided by
Dr. Carolyn Price [57] and were maintained in McCoy’s 5A media supplemented with
10% fetal bovine serum and 1% penicillin/streptomycin at 37ºC with 5% CO2. Cells were
checked regularly for mycoplasma contamination. To induce Cre-ER mediated
recombination of the CTC1 gene, a final concentration of 10 nM TAM was added to
CTC1F/F and CTC1F/F+Flag-CTC1 cells. The initial addition of TAM is indicated as day
0. At each passage, 10 nM TAM was again added to ensure CTC1 gene disruption. For
siRNA knockdown, 5 nM ON-TARGETplus siRNA SMART pools to p53 (L-00332900), ATM (L-003201-00-0005), ATR (L-003202-00-0005), CHK1 (L-003255-00-0005)
or a non-targeting control (D-001810-10-05) (Dharmacon) were transfected into cells
with Lipofectamine RNAiMAX (Thermo Fisher Scientific). siRNA treatment lasted 72 h
and began on day 8 after TAM addition. For Flag-TopBP1 transfection, cells were plated
24 h before transfection in 100 mm dishes at 1x106 cells. 12.5 μg of pcDNA3-TopBP1
was mixed with 25 μl of Polyethylenimine (1 mg/ml) (Polysciences) in a total volume of
550 μl for each transfection. The pcDNA3-TopBP1 plasmid was generously provided by
Dr. Weei-Chen Lin [124]. After 48 h, the cells were collected and whole cell protein
extraction performed (see below).
Whole Cell Protein Extraction
Cell pellets were lysed, sonicated and nuclease-treated, as previously described
[30]. The supernatant collected and protein concentration measured by BCA assay
(Thermo Fisher). The samples were then mixed with SDS-PAGE loading buffer and
analyzed by Western blot, as described below.
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Subcellular Fractionation for Protein Extraction
Cell pellets were lysed in 200 µL Buffer A (10 mM HEPES pH 7.9, 10 mM KCl,
1.5 mM MgCl2, 0.34 M Sucrose, 1 mM DTT, 0.1% Triton X-100, 1x phosphatase
inhibitors [4 mM β-glycerophosphate, 4 mM sodium vanadate, and 20 mM sodium
fluoride] and 1x protease inhibitors [1 µg/mL pepstatin A, 5 µg/mL leupeptin, 1 µg/mL
E64, 2 µg/mL aprotinin, and 5 µg/mL antipain]) and incubated on ice for 10 min. Cell
lysates were centrifuged at 4ºC 1300 x g for 5 min. The supernatant was transfered to a
new tube and excess cell debris was removed by centrifugation at 20,000 x g for 15 min
at 4ºC. The supernatant (souble fraction) was transfered to a new tube. Cell pellets
containing nuclei were resuspended in 100 µl Buffer B (3 mM EDTA pH 8.0, 0.2 mM
EGTA, 1 mM DTT, 1x phosphatase inhibitors, and 1x protease inhibitors) and incubated
on ice for 30 min with mixing at 15 and 30 min. The samples were then centrifuged at
2,000 x g for 5 min at 4ºC and the supernatant containing the soluble nuclear fraction was
transferred to a new tube. Cell pellets containing the chromatin bound fraction were
resuspended in 100 µL Buffer A and then sonicated at 40% amplitude for 3 cycles of 10
seconds on and 5 seconds rest. Samples were then treated with Benzonase (0.0625 U/ µL;
EMD Millipore) for 1 h on ice followed by centrifugation at 15,800 x g for 10 min at 4ºC
and the supernatant saved as the chromatin fraction. Protein concentrations were
determined with the BCA assay and samples analyzed by Western blot, as described
below.
Western Blot Analysis
20-40 µg of protein were run by SDS-PAGE and transferred to a nitrocellulose
membrane. All membranes were checked with Ponceau S staining for transfer efficiency
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and total protein loading. Membranes to analyze CTC1 levels were blocked with 3%
BSA in 1xPBS plus 0.1% Tween 20 (PBST) for at least 2 h, and all subsequent antibodies
were diluted in 3% BSA-PBST. For analysis of CHK1 S317, membranes were blocked in
5% non-fat milk in 1xTBS plus 0.1% Tween 20 (TBST) for at least 2 h, and all
subsequent antibodies were diluted in 5% non-fat milk-TBST. For all other western blots,
membranes were blocked in 5% non-fat milk-PBST for at least 2 h. Primary antibodies
were diluted in 5% non-fat milk-PBST and incubated at 4˚C overnight. The membranes
were then washed 3 x for 10 min each in PBST (TBST for pCHK1 S317). Secondary
antibodies were diluted in the solution indicated above for at least 2 h at room
temperature. After incubation the blots were then developed with Western Lightning Plus
ECL (Perkin Elmer) or ECL Prime (GE Healthcare).
Caspase-Glo 3/7 Assay
Active apoptosis was measured using the Promega Caspase-Glo 3/7 Assay
(G8090), according to the manufacturer’s instructions. DMSO or 5 µM VE-821 (ATRi)
was added for 24 h, as indicated. Each treatment was performed in triplicate and at least
three independent, biological replicates performed. The luciferase activity was measured
on a Spectra Max i3 (Molecular Devices) and analyzed by Softmax Pro 6 (Molecular
Devices).
Flow Cytometry
The cells were collected and washed with 1x PBS. After the supernatant was
removed, 5 mL of ice-cold 100% methanol was added drop wise with gentle vortexing.
Tubes were then placed at -20ºC for 10 min followed by centrifugation at 2000 x g for 5
min. The supernatant was removed and the cell pellets were washed with 5 mL 1x PBS
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and centrifuged again at 2000 x g for 5 min. Cell pellets were then stored at 4ºC at least
overnight.
To detect S-phase cells, EdU (50 M) was added 30 min prior to collection. EdU
was detected by Click-iT chemistry, according to the manufacturer’s instructions
(Thermo Fisher). Cells were resuspended in 250 µL of Click-iT reaction cocktail and
incubated for 30 min at RT protected from light. 5 mL of 1% BSA-PBST was then added
and samples were spun down at 1000 x g for 5 min and the supernatant removed. The
cells were then resuspended in 650 µL of fresh DAPI Staining Solution (0.1% Triton X100, 0.1 mg/mL RNase, 1 µg/mL DAPI diluted in 1 x PBS). The samples were spun at 50
x g for 30 s to remove cell clumps and debris through filter-capped tubes (Corning) and
run on a BD LSR II Flow Cytometer in the Microscopy and Flow Cytometry Facility at
the University of South Carolina, College of Pharmacy. At least 10,000 cells were
analyzed per experiment.
RPA Flow Cytometry
Cells were collected and washed with 1x PBS. After the supernatant was
removed, the cell pellets were resuspended in 500 µl 1x CSK buffer (10 mM HEPES pH
7.4, 300 mM sucrose, 100 mM NaCl, and 3 mM MgCl2 diluted in ddH2O) with 0.1%
Triton-X and incubated at room temperature for 5 min. Then, with gentle vortexing, 5 mL
of ice-cold 100% methanol was added to the tubes drop wise. Tubes were then placed at 20ºC for 10 min. Then 5 mL of 1% BSA-PBS was added to the samples followed by
centrifugation at 2000 x g for 5 min. The supernatant was removed and the cell pellets
were resuspended in 5 mL 1% BSA-PBS. Samples were then stored at 4ºC at least
overnight. For analysis of chromatin-bound RPA, cells were centrifuged at 2000 x g for 5
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min and the supernatant removed. The cell pellets were resuspended in 5 mL of 1% BSAPBST and incubated at room temperature for 15 min. Samples were spun down at 1000 x
g for 5 min. The supernatant was removed and the cell pellet was resuspended in 200 µL
of RPA32 primary antibody diluted in 1% BSA-PBST (1:500). The samples were
incubated with the primary antibody for at least 1 h at RT with mild vortexing halfway
through incubation. 5 mL of 1% BSA-PBST was then added. Samples were spun down at
1000 x g for 5 min and the supernatant was removed. Cells were resuspended and
incubated in 200 µL of goat α-mouse AlexaFluor 647 (1:500) in 1% BSA-PBST for at
least 1 h at RT, protected from light, with mild vortexing halfway through incubation.
Afterwards, 5 mL of 1% BSA-PBST was added and samples were spun down at 1000 x g
for 5 min and the supernatant was removed.
DNA combing
Cells were labeled with IdU (50 M) for 30 min, washed three times with 1x PBS
and then labeled with CldU (100 M) for 30 min. Cells were then collected, washed once
with 1x PBS and diluted to ~3,300/l. Agarose plugs were then made and prepared for
DNA combing, as previously described (31127588). DNA fibers were combed on
silanized coverslips according to the manufacturer’s instructions (Genomic Vision).
Coverslips were then baked at 80C for 2 h, washed once with 1x PBS and denatured
with 0.5 M NaOH/1 M NaCl for 8 min. Following two 1x PBS washes, the coverslips
were blocked in 3% BSA/1x PBS for 30 min followed by incubation with two -BrdU
antibodies (Accurate Chemical [OBT0030] and BD [347580]) (1:100), each with
specificity to either IdU or CldU, for 2 h at 37C. After three PBST washes, goat αmouse AlexaFluor 594 and goat α-rat AlexaFluor 488 (1:500) secondary antibodies were
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incubated on the coverslips for 1 h at 37C. Coverslips were washed three times with 1x
PBST, dehydrated and mounted on slides with mounting media. Images were then taken
under a 40x objective on an EVOS epifluorescence microscope (Thermo) and scored
using ImageJ.
IF and IF-FISH
Cells were plated onto coverslips and allowed to grow for 24 hours to 50-70%
confluency. 50 µM EdU was added for 30 min prior to collection. For detection of
phosphorylated H2AX S140 (H2AX), Histone H3 Ser10, and RPA32 Ser33, cells were
fixed with 4% formaldehyde in 1 x PBS for 10 min at RT. After formaldehyde
incubation, cells were rinsed twice with 1x PBS and then permeabilized with 0.5% Triton
X-100 diluted in 1 x PBS for 10 min at RT. Slides were washed with 1 x PBS then stored
4˚C overnight in 1x PBS. For detection of chromatin-bound RPA32, cells were preextracted with 0.1% Triton X-100 in 1 x CSK buffer (10 mM HEPES pH 7.4, 300 mM
Sucrose, 100 mM NaCl, 3 mM MgCl2) for 5 min at room temperature. Slides were then
washed once with 1 x PBS and fixed by adding 100% ice cold methanol. Slides were
incubated at -20˚C for 10 min, washed with 1 x PBS and then stored at 4˚C overnight in
1x PBS. IF was then performed as previous described for H2AX (1:5000),
phosphorylated Histone H3 S10 (1:500), phosphorylated RPA32 S33 (1:1000) or RPA32
(1:500) [30]. Nuclear signal intensity of H2AX was measured in ImageJ as previously
described [30].
For IF-FISH, IF was performed for chromatin-bound RPA32, as described above.
Telomere FISH was then performed, as previously described [125]. Briefly, after the last
wash, following secondary antibody incubation, the coverslips were fixed with 2%
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formaldehyde in 1x PBS for 10 min at RT. After two washes with 1x PBS, the coverslips
were dehydrated and incubated with a telomeric G-strand PNA probe (AlexaFluor 488TTAGGG3; PNA Bio) in hybridization buffer (10 mM Tris pH 7.4, 70% formamide, 1%
blocking reagent [Roche]) for 10 min at 80C. Coverslips were then incubated at RT for
2-3 h followed by two washes in wash buffer (10 mM Tris pH 7.4, 70% formamide) for
15 min each. The coverslips were subsequently washed three times with 1x PBS,
dehydrated and mounted on slides with mounting media containing 0.2 g/ml DAPI. IF
and IF-FISH images were then taken under 40x or 60x objectives on an EVOS
epifluorescence microscope (Thermo). Foci and co-localizing foci were scored using
ImageJ.
Antibodies and Chemical Inhibitors
Primary: CTC1 [57], STN1 (Abcam, 119263), Actinin (Santa Cruz, sc17829), Tubulin (Sigma, T-9026), ATM (Cell Signaling 2837), ATR (Cell Signaling 13934S),
ATR T1989 (Cell Signaling 30632S), CHK1 (Bethyl, A300-298A), CHK1 S317 (Bethyl,
A304-673A), CHK1 S345 (Cell Signaling, 2348T), p53 (Cell Signaling, 9282), p21
(Santa Cruz, sc-6246), H3 (Cell Signaling, 9715), pH3 S10 (Cell Signaling, 9706), Rad9
(Santa Cruz, sc-74464), RPA32 (Abcam, ab16850), pRPA32 S33 (Bethyl, A300-246A),
TopBP1 (Bethyl, A300-111A), ETAA1 (kindly provided by Dr. David Cortez), γH2AX
(Bethyl, A300-081A) and POT1 (Abcam, ab124784). Secondary: Thermo: anti-rabbitHRP (32460); anti-mouse-HRP (32430); Molecular Probes: goat-anti-rabbit AlexaFluor
647 (A21244), goat-anti-mouse AlexaFluor 647 (A21235), goat-anti-mouse AlexaFluor
594 (A11032), goat-anti-rabbit AlexaFluor 594 (A11037). ATR inhibitor: VE-821 5 µM
for 24 h (Selleckchem, S8007).
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Frontiers in Bioscience on [2018 Mar], available online:
https://www.bioscience.org/2018/v23/af/4661/fulltext.htm
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APPENDIX C
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY REPRINT
PERMISSIONS
This contains portions of a Provisionally Accepted Manuscript of an article published by
Frontiers in Frontiers in Cell and Developmental Biology on [2021 July], available
online: https://www.frontiersin.org/articles/10.3389/fcell.2021.708763/abstract
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